


#4



ENTERICALLY TRANSMITTED NON-A/NON-B HEPATITIS
VIRAL AGENT AND CHARACTERISTIC EPITOPES THEREOF

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. Application
Serial No. 08/279,823, filed July 25, 1994, which is a
continuation of U.S. Application Serial No. 07/681,078, filed
April 5, 1991, now abandoned, which is a continuation-in-part
10 of U.S. Application Serial No. 07/505,888, filed April 5, 1990,
now abandoned, which is a continuation-in-part of U.S.
Application Serial No. 07/420,921, filed October 13, 1989, now
abandoned, which is a continuation-in-part of U.S. Application
Serial No. 07/367,486, filed June 16, 1989, now abandoned,
15 which is a continuation-in-part of U.S. Application Serial No.
07/336,672, filed April 11, 1989, now abandoned, which is a
continuation-in-part of U.S. Application Serial No. 07/208,997,
filed June 17, 1988, now abandoned, all of which are herein
incorporated by reference.

20

INTRODUCTION

Field of Invention

This invention relates to recombinant proteins, genes,
and gene probes and more specifically to such proteins and
25 probes derived from an enterically transmitted nonA/nonB
hepatitis viral agent, to diagnostic methods and vaccine
applications which employ the proteins and probes, and to gene
segments that encode specific epitopes (and proteins
artificially produced to contain those epitopes) that are
30 particularly useful in diagnosis and prophylaxis.

Background

Enterically transmitted non-A/non-B hepatitis viral
agent (ET-NANB; also referred to herein as HEV) is the reported
35 cause of hepatitis in several epidemics and sporadic cases in
Asia, Africa, Europe, Mexico, and the Indian subcontinent.
Infection is usually by water contaminated with feces, although

09551410.021988

the virus may also spread by close physical contact. The virus does not seem to cause chronic infection. The viral etiology in ET-NANB has been demonstrated by infection of volunteers with pooled fecal isolates; immune electron microscopy (IEM) studies have shown virus particles with 27-34 nm diameters in stools from infected individuals. The virus particles reacted with antibodies in serum from infected individuals from geographically distinct regions, suggesting that a single viral agent or class is responsible for the majority of ET-NANB hepatitis seen worldwide. No antibody reaction was seen in serum from individuals infected with parenterally transmitted NANB virus (also known as hepatitis C virus or HCV), indicating a different specificity between the two NANB types.

In addition to serological differences, the two types of NANB infection show distinct clinical differences. ET-NANB is characteristically an acute infection, often associated with fever and arthralgia, and with portal inflammation and associated bile stasis in liver biopsy specimens (Arankalle). Symptoms are usually resolved within six weeks. Parenterally transmitted NANB, by contrast, produces a chronic infection in about 50% of the cases. Fever and arthralgia are rarely seen, and inflammation has a predominantly parenchymal distribution (Khuroo, 1980). The course of ET-NANBH is generally uneventful in healthy individuals, and the vast majority of those infected recover without the chronic sequelae seen with HCV. One peculiar epidemiologic feature of this disease, however, is the markedly high mortality observed in pregnant women; this is reported in numerous studies to be on the order of 10-20%. This finding has been seen in a number of epidemiologic studies but at present remains unexplained. Whether this reflects viral pathogenicity, the lethal consequence of the interaction of virus and immune suppressed (pregnant) host, or a reflection of the

debilitated prenatal health of a susceptible
malnourished population remains to be clarified.

The two viral agents can also be distin-
guished on the basis of primate host susceptibility.
5 ET-NANB, but not the parenterally transmitted agent,
can be transmitted to cynomolgus monkeys. The
parenterally transmitted agent is more readily
transmitted to chimpanzees than is ET-NANB (Bradley,
1987).

10 There have been major efforts worldwide to
identify and clone viral genomic sequences associated
with ET-NANB hepatitis. One goal of this effort,
requiring virus-specific genomic sequences, is to
identify and characterize the nature of the virus and
15 its protein products. Another goal is to produce
recombinant viral proteins which can be used in
antibody-based diagnostic procedures and for a
vaccine. Despite these efforts, viral sequences
associated with ET-NANB hepatitis have not been
20 successfully identified or cloned heretofore, nor have
any virus-specific proteins been identified or
produced.

Relevant Literature

- 25 Arankalle, V.A., et al., The Lancet, 550
(March 12, 1988).
Bradley, D.W., et al., J Gen. Virol., 69:1
(1988).
Bradley, D.W. et al., Proc. Nat. Acad. Sci.,
30 USA, 84:6277 (1987).
Gravelle, C.R. et al., J. Infect. Diseases,
131:167 (1975).
Kane, M.A., et al., JAMA, 252:3140 (1984).
Khuroo, M.S., Am. J. Med., 48:818 (1980).
35 Khuroo, M.S., et al., Am. J. Med., 68:818
(1983).

Maniatis, T., et al. Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory (1982).

Seto, B., et al., Lancet, 11:941 (1984).

5 Sreenivasan, M.A., et al., J. Gen. Virol., 65:1005 (1984).

Tabor, E., et al., J. Infect. Dis., 140:789 (1979).

10 SUMMARY OF THE INVENTION

Novel compositions, as well as methods of preparation and use of the compositions are provided, where the compositions comprise viral proteins and fragments thereof derived from the viral agent for ET-NANB. A number of specific fragments of viral proteins (and the corresponding genetic sequences) that are particularly useful in diagnosis and vaccine production are also disclosed. Methods for preparation of ET-NANB viral proteins include isolating ET-NANB genomic sequences which are then cloned and expressed in a host cell. The resultant recombinant viral proteins find use as diagnostic agents and as vaccines. The genomic sequences and fragments thereof find use in preparing ET-NANB viral proteins and as probes for virus detection.

15
20
25

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 shows vector constructions and manipulations used in obtaining and sequencing cloned ET-NANB fragment; and

30

Figures 2A-2B are representations of Southern blots in which a radiolabeled ET-NANB probe was hybridized with amplified cDNA fragments prepared from RNA isolated from infected (I) and non-infected (N) bile sources (2A), and from infected (I) and non-infected (N) stool-sample sources (2B).

35

DESCRIPTION OF SPECIFIC EMBODIMENTS

Novel compositions comprising generic sequences and fragments thereof derived from the viral agent for ET-NANB are provided, together with
5 recombinant viral proteins produced using the genomic sequences and methods of using these compositions. Epitopes on the viral protein have been identified that are particularly useful in diagnosis and vaccine production. Small peptides containing the epitopes are
10 recognized by multiple sera of patients infected with ET-NANB.

The molecular cloning of HEV was accomplished by two very different approaches. The first successful identification of a molecular clone was
15 based on the differential hybridization of putative HEV cDNA clones to heterogeneous cDNA from infected and uninfected cyno bile. cDNAs from both sources were labeled to high specific activity with ^{32}P to identify a clone that hybridized specifically to the
20 infected source probe. A cyno monkey infected with the Burma isolate of HEV was used in these first experiments. The sensitivity of this procedure is directly related to the relative abundance of the specific sequence against the overall background. In
25 control experiments, it was found that specific identification of a target sequence may be obtained with as little as 1 specific part per 1000 background sequences. A number of clones were identified by this procedure using libraries and probes made from
30 infected (Burma isolate) and control uninfected cyno bile. The first extensively characterized clone of the 16 plaques purified by this protocol was given the designation ET1.1.

ET1.1 was first characterized as both
35 derived from and unique to the infected source cDNA. Heterogeneous cDNA was amplified from both infected and uninfected sources using a sequence independent single premier amplification technique (SISPA). This

technique is described in copending application serial No. 208,512, filed June 17, 1988. The limited pool of cDNA made from Burma infected cyno bile could then be amplified enzymatically prior to cloning or
5 hybridization using putative HEV clones as probes. ET1.1 hybridized specifically to the original bile cDNA from the infected source. Further validation of this clone as derived from the genome of HEV was demonstrated by the similarity of the ET1.1 sequence
10 and those present in SISPA cDNA prepared from five different human stool samples collected from different ET-NANBH epidemics including Somalia, Tashkent, Borneo, Mexico and Pakistan. These molecular epidemiologic studies established the
15 isolated sequence as derived from the virus that represented the major cause of ET-NANBH worldwide.

The viral specificity of ET1.1 was further established by the finding that the clone hybridized specifically to RNA extracted from infected cyno
20 liver. Hybridization analysis of polyadenylated RNA demonstrated a unique 7.5 Kb polyadenylated transcript not present in uninfected liver. The size of this transcript suggested that it represented the full length viral genome. Strand specific
25 oligonucleotides were also used to probe viral genomic RNA extracted directly from semi-purified virions prepared from human stool. The strand specificity was based on the RNA-directed RNA polymerase (RDRP) open reading frame (ORF) identified in ET1.1 (see below).
30 Only the probe detecting the sense strand hybridized to the nucleic acid. These studies characterized HEV as a plus sense, single stranded genome. Strand specific hybridization to RNA extracted from the liver also established that the vast majority of
35 intracellular transcript was positive sense. Barring any novel mechanism for virus expression, the negative strand, although not detectable, would be present at a

ratio of less than 1:100 when compared with the sense strand.

ET1.1 was documented as exogenous when tested by both Southern blot hybridization and PCR using genomic DNAs derived from uninfected humans, infected and uninfected cynos and also the genomic DNAs from E. coli and various bacteriophage sources. The latter were tested in order to rule out trivial contamination with an exogenous sequence introduced during the numerous enzymatic manipulations performed during cDNA construction and amplification. It was also found that the nucleotide sequence of the ET1.1 clone was not homologous to any entries in the Genebank database. The translated open reading frame of the ET1.1 clone did, however, demonstrate limited homology with consensus amino acid residues consistent with an RNA-directed RNA polymerase. This consensus amino acid motif is shared among all positive strand RNA viruses and, as noted above, is present at the 3' end of the HCV genome. The 1.3 Kb clone was therefore presumed to be derived, at least in part, from the nonstructural portion of the viral genome.

Because of the relationship of different strains of ET-NANB to each other that has been demonstrated by the present invention, the genome of the ET-NANB viral agent is defined in this specification as containing a region which is homologous to the 1.33 kb DNA EcoRI insert present in plasmid pTZKF1 (ET1.1) carried in E. coli strain BB4 and having ATCC deposit no. 67717. The entire sequence, in both directions, has now been identified as set forth below. The sequences of both strands are provided, since both strands can encode proteins. However, the sequence in one direction has been designated as the "forward" sequence because of statistical similarities to known proteins and because the forward sequence is known to be predominately protein-encoding. This sequence is set forth below

along with the three possible translation sequences. There is one long open reading frame that starts at nucleotide 145 with an isoleucine and extends to the end of the sequence. The two other reading frames have many termination codons. Standard abbreviations for nucleotides and amino acids are used here and elsewhere in this specification.

The gene sequence given below is substantially identical to one given in the parent application. The present sequence differs in the omission of the first 37 nucleotides at the 5' end and last 13 nucleotides at the 3' end, which are derived from the linker used for cloning rather than from the virus. In addition, a G was omitted at position 227 of the sequence given in the parent application.

The following gene sequence has SEQ ID NO.1; the first amino acid sequence in reading frame beginning with nucleotide 1 has SEQ ID NO.2; the second amino acid sequence in reading frame beginning with nucleotide 2 has SEQ ID NO.3; and the third amino acid sequence in reading frame beginning with nucleotide 3 has SEQ ID NO.4.

Forward Sequence

SEQ ID NO. 1:

25	AGACCTGTCC CTGTTGCAGC TGTCTACCA CCCTGCCCCG AGCTCGAACA GGGCCTTCTC	60
	TACCTGCCCC AGGAGCTCAC CACCTGTGAT AGTGTCTGTA CATTGAATT AACAGACATT	120
30	GTGCACTGCC GCATGGCCGC CCCGAGCCAG CGCAAGGCCG TGCTGTCCAC ACTCGTGGGC	180
	CGCTACGGCG GTCGCACAAA GCTCTACAAT GCTTCCCACT CTGATGTTTC GCACTCTCTC	240
35	GCCCGTTTTA TCCCGGCCAT TGGCCCCGTA CAGGTTACAA CTTGTGAATT GTACGAGCTA	300
	GTGGAGGCCA TGGTCGAGAA GGGCCAGGAT GGCTCCGCCG TCCTTGAGCT TGATCTTTGC	360
	AACCGTGACG TGTCCAGGAT CACCTTCTTC CAGAAAGATT GTAACAAGTT CACCACAGGT	420
40	GAGACCATTG CCCATGGTAA AGTGGGCCAG GGCATCTCGG CCTGGAGCAA GACCTTCTGC	480
	GCCCTCTTTG GCCCTTGGTT CCGCGCTATT GAGAAGGCTA TTCTGGCCCT GCTCCCTCAG	540
45	GGTGTGTTTT ACGGTGATGC CTTTGATGAC ACCGTCTTCT CGGCGGCTGT GGCCGCAGCA	600

AAGGCATCCA TGGTGTGTTGA GAATGACTTT TCTGAGTTTG ACTCCACCCA GAATAACTTT 660
 TCTCTGGGTC TAGAGTGTGC TATTATGGAG GAGTGTGGGA TGCCGCAGTG GCTCATCCGC 720
 5 CTGTATCACC TTATAAGGTC TGCCTGGATC TTGCAGGCCC CGAAGGAGTC TCTGCGAGGG 780
 TTTTGAAGA AACACTCCGG TGAGCCCGGC ACTCTTCTAT GGAATACTGT CTGGAATATG 840
 GCCGTATTA CCCACTGTGA TGAATTCCGC GATTTTCAGG TGGCTGCCTT TAAAGGTGAT 900
 10 GATTCGATAG TGCTTTGCAG TGAGTATCGT CAGAGTCCAG GAGCTGCTGT CCTGATCGCC 960
 GGCTGTGGCT TGAAGTTGAA GGTAGATTC CGCCCGATCG GTTTGTATGC AGGTGTTGTG 1020
 15 GTGGCCCCCG GCCTTGGCGC GCTCCCTGAT GTTGTGCGCT TCGCCGGCCG GCTTACCGAG 1080
 AAGAATTGGG GCCCTGGCCC TGAGCGGGCG GAGCAGCTCC GCCTCGCTGT TAGTGATTTT 1140
 CTCGCAAGC TCACGAATGT AGCTCAGATG TGTGTGGATG TTGTTTCCCG TGTTTATGGG 1200
 20 GTTTCCCTG GACTCGTTCA TAACCTGATT GGCATGCTAC AGGCTGTTGC TGATGGCAAG 1260
 GCACATTTC CTGAGTCAGT AAAACCAGTG CTCGA 1295
 25 SEQ ID NO. 2:
 Arg Pro Val Pro Val Ala Ala Val Leu Pro Pro Cys Pro Glu Leu Glu
 1 5 10 15
 30 Gln Gly Leu Leu Tyr Leu Pro Gln Glu Leu Thr Thr Cys Asp Ser Val
 20 25 30
 Val Thr Phe Glu Leu Thr Asp Ile Val His Cys Arg Met Ala Ala Pro
 35 35 40 45
 35 Ser Gln Arg Lys Ala Val Leu Ser Thr Leu Val Gly Arg Tyr Gly Gly
 50 55 60
 40 Arg Thr Lys Leu Tyr Asn Ala Ser His Ser Asp Val Arg Asp Ser Leu
 65 70 75 80
 Ala Arg Phe Ile Pro Ala Ile Gly Pro Val Gln Val Thr Thr Cys Glu
 85 90 95
 45 Leu Tyr Glu Leu Val Glu Ala Met Val Glu Lys Gly Gln Asp Gly Ser
 100 105 110
 Ala Val Leu Glu Leu Asp Leu Cys Asn Arg Asp Val Ser Arg Ile Thr
 115 120 125
 50 Phe Phe Gln Lys Asp Cys Asn Lys Phe Thr Thr Gly Glu Thr Ile Ala
 130 135 140
 55 His Gly Lys Val Gly Gln Gly Ile Ser Ala Trp Ser Lys Thr Phe Cys
 145 150 155 160

0051410-051902

	Ala Leu Phe Gly Pro Trp Phe Arg Ala Ile Glu Lys Ala Ile Leu Ala	165	170	175
5	Leu Leu Pro Gln Gly Val Phe Tyr Gly Asp Ala Phe Asp Asp Thr Val	180	185	190
	Phe Ser Ala Ala Val Ala Ala Ala Lys Ala Ser Met Val Phe Glu Asn	195	200	205
10	Asp Phe Ser Glu Phe Asp Ser Thr Gln Asn Asn Phe Ser Leu Gly Leu	210	215	220
	Glu Cys Ala Ile Met Glu Glu Cys Gly Met Pro Gln Trp Leu Ile Arg	225	230	240
15	Leu Tyr His Leu Ile Arg Ser Ala Trp Ile Leu Gln Ala Pro Lys Glu	245	250	255
	Ser Leu Arg Gly Phe Trp Lys Lys His Ser Gly Glu Pro Gly Thr Leu	260	265	270
20	Leu Trp Asn Thr Val Trp Asn Met Ala Val Ile Thr His Cys Tyr Asp	275	280	285
	Phe Arg Asp Phe Gln Val Ala Ala Phe Lys Gly Asp Asp Ser Ile Val	290	295	300
25	Leu Cys Ser Glu Tyr Arg Gln Ser Pro Gly Ala Ala Val Leu Ile Ala	305	310	320
30	Gly Cys Gly Leu Lys Leu Lys Val Asp Phe Arg Pro Ile Gly Leu Tyr	325	330	335
	Ala Gly Val Val Val Ala Pro Gly Leu Gly Ala Leu Pro Asp Val Val	340	345	350
35	Arg Phe Ala Gly Arg Leu Thr Glu Lys Asn Trp Gly Pro Gly Pro Glu	355	360	365
40	Arg Ala Glu Gln Leu Arg Leu Ala Val Ser Asp Phe Leu Arg Lys Leu	370	375	380
	Thr Asn Val Ala Gln Met Cys Val Asp Val Val Ser Arg Val Tyr Gly	385	390	400
45	Val Ser Pro Gly Leu Val His Asn Leu Ile Gly Met Leu Gln Ala Val	405	410	415
	Ala Asp Gly Lys Ala His Phe Thr Glu Ser Val Lys Pro Val Leu	420	425	430

SEQ ID NO. 3:

55	Asp Leu Ser Leu Leu Gln Leu Phe Tyr His Pro Ala Pro Ser Ser Asn	1	5	10	15
----	---	---	---	----	----

09851410-021902

	Arg Ala Phe Ser Thr Cys Pro Arg Ser Ser Pro Pro Val Ile Val Ser	
	20 25 30	
5	His Leu Asn Gln Thr Leu Cys Thr Ala Ala Trp Pro Pro Arg	
	35 40 45	
	Ala Ser Ala Arg Pro Cys Cys Pro His Ser Trp Ala Ala Thr Ala Val	
	50 55 60	
10	Ala Gln Ser Ser Thr Met Leu Pro Thr Leu Met Phe Ala Thr Leu Ser	
	65 70 75 80	
	Pro Val Leu Ser Arg Pro Leu Ala Pro Tyr Arg Leu Gln Leu Val Asn	
	85 90 95	
15	Cys Thr Ser Trp Arg Pro Trp Ser Arg Arg Ala Arg Met Ala Pro	
	100 105 110	
	Pro Ser Leu Ser Leu Ile Phe Ala Thr Val Thr Cys Pro Gly Ser Pro	
	115 120 125	
20	Ser Ser Arg Lys Ile Val Thr Ser Ser Pro Gln Val Arg Pro Leu Pro	
	130 135 140	
	Met Val Lys Trp Ala Arg Ala Ser Arg Pro Gly Ala Arg Pro Ser Ala	
	145 150 155 160	
	Pro Ser Leu Ala Leu Gly Ser Ala Leu Leu Arg Arg Leu Phe Trp Pro	
	165 170 175	
30	Cys Ser Leu Arg Val Cys Phe Thr Val Met Pro Leu Met Thr Pro Ser	
	180 185 190	
	Ser Arg Arg Leu Trp Pro Gln Gln Arg His Pro Trp Cys Leu Arg Met	
	195 200 205	
35	Thr Phe Leu Ser Leu Thr Pro Pro Arg Ile Thr Phe Leu Trp Val	
	210 215 220	
	Ser Val Leu Leu Trp Arg Ser Val Gly Cys Arg Ser Gly Ser Ser Ala	
	225 230 235 240	
	Cys Ile Thr Leu Gly Leu Arg Gly Ser Cys Arg Pro Arg Arg Ser	
	245 250 255	
45	Leu Cys Glu Gly Phe Gly Arg Asn Thr Pro Val Ser Pro Ala Leu Phe	
	260 265 270	
	Tyr Gly Ile Leu Ser Gly Ile Trp Pro Leu Leu Pro Thr Val Met Thr	
	275 280 285	
50	Ser Ala Ile Phe Arg Trp Leu Pro Leu Lys Val Met Ile Arg Cys	
	290 295 300	
	Phe Ala Val Ser Ile Val Arg Val Gln Glu Leu Leu Ser Ser Pro	
	305 310 315 320	

Ala Val Ala . Ser . Arg . Ile Ser Ala Arg Ser Val Cys Met
325 330 335

5 Gln Val Leu Trp Trp Pro Pro Ala Leu Ala Arg Ser Leu Met Leu Cys
340 345 350

Ala Ser Pro Ala Gly Leu Pro Arg Arg Ile Gly Ala Leu Ala Leu Ser
355 360 365

10 Gly Arg Ser Ser Ser Ala Ser Leu Leu Val Ile Ser Ser Ala Ser Ser
370 375 380

Arg Met . Leu Arg Cys Val Trp Met Leu Phe Pro Val Phe Met Gly
385 390 395 400

15 Phe Pro Leu Asn Ser Phe Ile Thr . Leu Ala Cys Tyr Arg Leu Leu
405 410 415

20 Leu Met Ala Arg His Ile Ser Leu Ser Gln . Asn Gln Cys Ser
420 425 430

SEQ ID NO. 4:

25 Thr Cys Pro Cys Cys Ser Cys Ser Thr Thr Leu Pro Arg Ala Arg Thr
1 5 10 15

Gly Pro Ser Leu Pro Ala Pro Gly Ala His His Leu . . Cys Arg
20 25 30

30 Asn Ile . Ile Asn Arg His Cys Ala Leu Pro His Gly Arg Pro Glu
35 40 45

35 Pro Ala Gln Gly Arg Ala Val His Thr Arg Gly Pro Leu Arg Arg Ser
50 55 60

His Lys Ala Leu Gln Cys Phe Pro Leu . Cys Ser Arg Leu Ser Arg
65 70 75 80

40 Pro Phe Tyr Pro Gly His Trp Pro Arg Thr Gly Tyr Asn Leu . Ile
85 90 95

Val Arg Ala Ser Gly Gly His Gly Arg Glu Gly Pro Gly Trp Leu Arg
100 105 110

45 Arg Pro . Ala . Ser Leu Gln Pro . Arg Val Gln Asp His Leu
115 120 125

50 Leu Pro Glu Arg Leu . Gln Val His His Arg . Asp His Cys Pro
130 135 140

Trp . Ser Gly Pro Gly His Leu Gly Leu Glu Gln Asp Leu Leu Arg
145 150 155 160

55 Pro Leu Trp Pro Leu Val Pro Arg Tyr . Glu Gly Tyr Ser Gly Pro
165 170 175

09654410-021902

	Ala Pro Ser Gly Cys Val Leu Arg . Cys Leu . . His Arg Leu	
	180 185 190	
5	Leu Gly Gly Cys Gly Arg Ser Lys Gly Ile His Gly Val . Glu .	
	195 200 205	
	Leu Phe . Val . Leu His Pro Glu . Leu Phe Ser Gly Ser Arg	
	210 215 220	
10	Val Cys Tyr Tyr Gly Gly Val Trp Asp Ala Ala Val Ala His Pro Pro	
	225 230 235 240	
	Val Ser Pro Tyr Lys Val Cys Val Asp Leu Ala Gly Pro Glu Gly Val	
15	245 250 255	
	Ser Ala Arg Val Leu Glu Glu Thr Leu Arg . Ala Arg His Ser Ser	
	260 265 270	
20	Met Glu Tyr Cys Leu Glu Tyr Gly Arg Tyr Tyr Pro Leu Leu . Leu	
	275 280 285	
	Pro Arg Phe Ser Gly Gly Cys Leu . Arg . . Phe Asp Ser Ala	
25	290 295 300	
	Leu Gln . Val Ser Ser Glu Ser Arg Ser Cys Cys Pro Asp Arg Arg	
	305 310 315 320	
	Leu Trp Leu Glu Val Glu Gly Arg Phe Pro Pro Asp Arg Phe Val Cys	
30	325 330 335	
	Arg Cys Cys Gly Gly Pro Arg Pro Trp Arg Ala Pro . Cys Cys Ala	
	340 345 350	
35	Leu Arg Arg Pro Ala Tyr Arg Glu Glu Leu Gly Pro Trp Pro . Ala	
	355 360 365	
	Gly Gly Ala Ala Pro Pro Arg Cys . . Phe Pro Pro Gln Ala His	
40	370 375 380	
	Glu Cys Ser Ser Asp Val Cys Gly Cys Cys Phe Pro Cys Leu Trp Gly	
	385 390 395 400	
	Phe Pro Trp Thr Arg Ser . Pro Asp Trp His Ala Thr Gly Cys Cys	
45	405 410 415	
	. Trp Gln Gly Thr Phe His . Val Ser Lys Thr Ser Ala Arg	
	420 425 430	

50 The complementary strand, referred to here as the "reverse sequence," is set forth below in the same manner as the forward sequence set forth above. Several open reading frames, shorter than the long open reading frame found in the forward sequence, can

be seen in this reverse sequence. Because of the relative brevity of the open reading frames in the reverse direction, they are probably not expressed.

The following gene sequence has SEQ ID NO.5.

5 Reverse Sequence

SEQ ID NO. 5:

	TCGAGCACTG GTTTTACTGA CTCAGTGAAA TGTGCCTTGC CATCAGCAAC AGCCTGTAGC	60
10	ATGCCAATCA GGTATGAAC GAGTCCAGGG GAAACCCCAT AAACACGGGA AACAACTCC	120
	ACACACATCT GAGCTACATT CGTGAGCTTG CGGAGGAAAT CACTAACAGC GAGGCGGAGC	180
	TGCTCCGCCC GCTCAGGGCC AGGGCCCCAA TTCTTCTCGG TAAGCCGGCC GGCGAAGCGC	240
15	ACAACATCAG GGAGCGCGCC AAGGCCGGGG GCCACCACAA CACCTGCATA CAAACCGATC	300
	GGGCGGAAAT CTACCTTCAA CTTCAAGCCA CAGCCGGCGA TCAGGACAGC AGCTCCTGGA	360
20	CTCTGACGAT ACTCACTGCA AAGCACTATC GAATCATCAC CTTTAAAGGC AGCCACCTGA	420
	AAATCGCGGA AGTCATAACA GTGGGTAATA ACGGCCATAT TCCAGACAGT ATTCCATAGA	480
	AGAGTGCCGG GCTCACCGBA GTGTTTCTTC CAAAACCTC GCAGAGACTC TTTCGGGGCC	540
25	TGCAAGATCC ACGCAGACCT TATAAGGTGA TACAGGCGGA TGAGCCACTG CGGCATCCCA	600
	CACTCCTCCA TAATAGCACA CTCTAGACCC AGAGAAAAGT TATTCTGGGT GGAGTCAAAC	660
30	TCAGAAAAGT CATTCTCAA CACCATGGAT GCCTTTGCTG CGGCCACAGC CGCCGAGAAG	720
	ACGGTGTCAT CAAAGGCATC ACCGTAAAAC ACACCCTGAG GGAGCAGGGC CAGAATAGCC	780
	TTCTCAATAG CGCGGAACCA AGGGCCAAAG AGGGCGCAGA AGGTCTTGCT CCAGGCCGAG	840
35	ATGCCCTGGC CCACTTTACC ATGGGCAATG GTCTCACCTG TGGTGAACCT GTTACAATCT	900
	TTCTGGAAGA AGGTGATCCT GGACACGTCA CGGTTGCAA GATCAAGCTC AAGGACGGCG	960
40	GAGCCATCCT GGCCCTTCTC GACCATGGCC TCCACTAGCT CGTACAATTC ACAAGTTGTA	1020
	ACCTGTACGG GGCCAATGGC CGGGATAAAA CGGGCGAGAG AGTCGGAAC ATCAGAGTGG	1080
	GAAGCATTGT AGAGCTTTGT GCGACCGCCG TAGCGGCCCA CGAGTGTTGA CAGCACGGCC	1140
45	TTGCGCTGGC TCGGGGCGGC CATGCGGCAG TGCACAATGT CTGTTAATTC AAATGTTACG	1200
	ACACTATCAC AGGTGGTGAG CTCCTGGGGC AGGTAGAGAA GGCCCTGTTT GAGCTCGGGG	1260
50	CAGGGTGGTA GAACAGCTGC AACAGGGACA GGTCT	1295

Identity of this sequence with sequences in etiologic agents has been confirmed by locating a

corresponding sequence in a viral strain isolated in
Burma. The Burmese isolate contains the following
sequence of nucleotides (one strand and open reading
frames shown). The following gene sequence has SEQ ID
5 NO.6; the protein sequence corresponding to ORF1 has
SEQ ID NO.7; ORF2 has SEQ ID NO.8; and ORF3 has SEQ ID
NO.9.

SEQUENCE OF HEV (BURMA STRAIN)
|-ORF1-->
M E A H Q F I K A P G
10 AGGCAGACCACATATGTGGTCGATGCCATGGAGGCCCATCAGTTTATTAAGGCTCCTGGC
I T T A I E Q A A L A A A N S A L A N A
15 ATCACTACTGCTATTGAGCAGGCTGCTCTAGCAGCGCCAACCTCTGCCCTGGCGAATGCT 120
V V V R P F L S H Q Q I E I L I N L M Q
GTGGTAGTTAGGCCTTTTCTCTCACCAGCAGATTGAGATCCTCATTAACCTAATGCAA
20 P R Q L V F R P E V F W N H P I Q R V I
CCTCGCCAGCTTGTTCGCCCCGAGGTTTCTGGAATCATCCATCCAGCGTGCATC 240
H N E L E L Y C R A R S G R C L E I G A
CATAACGAGCTGGAGCTTTACTGCCGCGCCGCTCCGGCCGCTGTCTTGAATTTGGCGCC
25 H P R S I N D N P N V V H R C F L R P V
CATCCCCGCTCAATAAATGATAATCCTAATGTGGTCCACCGCTGCTTCCTCCGCCCTGTT 360
G R D V Q R W Y T A P T R G P A A N C R
30 GGGCGTGATGTTTCAGCGCTGGTATACTGCTCCCACTCGCGGGCCGGTGCTAATTGCCGG
R S A L R G L P A A D R T Y C L D G F S
CGTTCGCGCTGCGCGGGCTTCCCGCTGCTGACCGCACTTACTGCCTCGACGGGTTTTCT 480
35 G C N F P A E T G I A L Y S L H D M S P
GGCTGTAACTTTCCGCGGAGACTGGCATCGCCCTTACTCCCTTCATGATATGTCACCA
S D V A E A M F R H G M T R L Y A A L H
40 TCTGATGTCGCCGAGGCCATGTTCCGCCATGGTATGACGCGGCTCTATGCCGCCCTCCAT 600
L P P E V L L P P G T Y R T A S Y L L I
CTTCGCTGAGGTCTGCTGCCCCCTGGCACATATCGACCGCATCGTATTGCTAATT
H D G R R V V V T Y E G D T S A G Y N H
45 CATGACGGTAGGCGCGTTGTGGTGACGTATGAGGGTGATACTAGTGTGTTACAACCAC 720
D V S N L R S W I R T T K V T G D H P L
GATGTCTCCAACCTTGGCTCTGATTAGAACCACCAAGGTTACCGGAGACCATCCCTC
50 V I E R V R A I G C H F V L L L T A A P
GTTATCGAGCGGGTTAGGGCATTGGCTGCCACTTTGTTCTTGTCTACGGCAGCCCCG 840
E P S P M P Y V P Y P R S T E V Y V R S
55 GAGCCATCACCTATGCCTTATGTTCTTACCCCCGGTCTACCGAGGTCTATGTCGATCG

0954410-031902

I F G P G G T P S L F P T S C S T K S T
ATCTTCGGCCCGGTGGCACCCCTTCCTTATTCACACCTCATGCTCCACTAAGTCGACC 960
F H A V P A H I W D R L M L F G A T L D
5 TTCCATGCTGTCCCTGCCCATATTTGGGACCGTCTTATGCTGTTGGGGCCACCTTGGAT
D Q A F C C S R L M T Y L R G I S Y K V
GACCAAGCCTTTTGTGCTCCCGTTTAAATGACCTACCTTCGCGGCATTAGCTACAAGGTC 1080
10 T V G T L V A N E G W N A S E D A L T A
ACTGTTGGTACCCTTGTGGCTAATGAAGGCTGGAATGCCTCTGAGGACGCCCTCACAGCT
V I T A A Y L T I C H Q R Y L R T Q A I
GTTATCACTGCCGCCTACCTTACCATTGCCACACGCGGTATCTCCGCACCCAGGCTATA 1200
15 S K G M R R L E R E H A Q K F I T R L Y
TCCAAGGGGATGCGTCTGGAACGGGAGCATGCCAGAAGTTTATAACACGCCCTCTAC
S W L F E K S G R D Y I P G R Q L E F Y
20 AGCTGGCTCTTCGAGAAGTCCGGCGGTGATTACATCCCTGGCCGTCAGTTGGAGTTCTAC 1320
A Q C R R W L S A G F H L D P R V L V F
GCCCAGTGCGAGGCGTGGCTCTCCGCGGCTTTCATCTTGATCCACGGGTGTTGGTTTTT
25 D E S A P C H C R T A I R K A L S K F C
GACGAGTCGGCCCCCTGCCATTGTAGGACCGCATCCGTAAGGCGCTCTCAAAGTTTTGC 1440
C F M K W L G Q E C T C F L Q P A E G A
30 TGCTTCATGAAGTGGCTTGGTCAGGAGTGACCTGCTTCCTTCAGCTGCAGAAGGCGCC
V G D Q G H D N E A Y E G S D V D P A E
GTCGGCGACCAAGGTCATGATAATGAAGCCTATGAGGGGTCCGATGTTGACCCTGCTGAG 1560
35 S A I S D I S G S Y V V P G T A L Q P L
TCCGCCATTAGTGACATATCTGGGTCTATGTCGTCCTGGCACTGCCCTCCAACCGCTC
Y Q A L D L P A E I V A R A G R L T A T
TACCAGGCCCTCGATCTCCCCGCTGAGATTGTGGCTCGCGCGGGCCGGCTGACCGCCACA 1680
40 V K V S Q V D G R I D C E T L L G N K T
GTAAAGGTCTCCAGGTGATGGGCGGATCGATTGCGAGACCCTTCTTGGTAACAAAACC
F R T S F V D G A V L E T N G P E R H N
45 TTTGCGACGTCGTTTGTGACGGGGCGGTCTTAGAGACCAATGGCCAGAGCGCCACAAT 1800
L S F D A S Q S T M A A G P F S L T Y A
CTCTCCTTCGATGCCAGTCAGAGCACTATGGCCGCTGGCCCTTTCAGTCTCACCTATGCC
A S A A G L E V R Y V A A G L D H R A V
50 GCCTCTGCAGCTGGGCTGGAGGTGCGCTATGTTGCTGCCGGGCTTGACCATCGGGCGGTT 1920
F A P G V S P R S A P G E V T A F C S A
TTTGCCCCGGTGTTCACCCCGGTCAGCCCCGGCGAGGTTACCGCCTTCTGCTCTGCC
55 L Y R F N R E A Q R H S L I G N L W F H
CTATACAGGTTTAAACGTGAGGCCACGCGCATTCGCTGATCGGTAACCTTATGGTTCCAT 2040
P E G L I G L F A P F S P G H V W E S A
60 CCTGAGGGACTCATTGGCCTCTTCGCCCCGTTTTTCGCCCGGGCATGTTTGGGAGTCGGCT

09851410.021902

N P F C G E S T L Y T R T W S E V D A V
AATCCATTCTGTGGCGAGAGCACACTTTACACCCGTA CTGGTCGGAGGTTGATGCCGTC 2160
S S P A R P D L G F M S E P S I P S R A
5 TCTAGTCCAGCCCGGCTGACTTAGGTTTTATGCTGAGCCTTCTATACCTAGTAGGGCC
A T P T L A A P L P P P A P D P S P P P
GCCACGCCTACCCTGGCGGCCCTCTACCCCCCTGCACCGGACCCTTCCCCCCTCCC 2280
10 S A P A L A E P A S G A T A G A P A I T
TCTGCCCCGGCGCTTGCTGAGCGGCTTCTGGCGCTACCGCGGGGCCCGGCCATACT
H Q T A R H R R L L F T Y P D G S K V F
CACCAGACGGCCCGCACCGCGCTGCTCTTCACCTACCGGATGGCTCTAAGGTATTC 2400
15 A G S L F E S T C T W L V N A S N V D H
GCCGGCTCGCTGTTGAGTCGACATGCACGTGGCTCGTTAACGCGTCTAATGTTGACCAC
R P G G G L C H A F Y Q R Y P A S F D A
20 CGCCCTGGCGGGGGCTTTGCCATGCATTTTACCAAAGGTACCCGCTCCTTTGATGCT 2520
A S F V M R D G A A A Y T L T P R P I I
GCCTCTTTTGATGCGCGACGGCGGGCGCGTACACACTAACCCCGGCCAATAATT
H A V A P D Y R L E H N P K R L E A A Y
25 CACGCTGTGCCCCCTGATTATAGGTTGGAACATAACCCAAAGAGGCTTGAGGCTGCTTAT 2640
R E T C S R L G T A A Y P L L G T G I Y
CGGGAACTTGCTCCCGCCTCGGCACCGCTGCATACCCGCTCCTCGGGACCGGCATATAC
30 Q V P I G P S F D A W E R N H R P G D E
CAGGTGCCGATCGGCCCCAGTTTTGACGCTGGGAGCGGAACCACCGCCCCGGGATGAG 2760
L Y L P E L A A R W F E A N R P T R P T
35 TTGTACCTTCTGAGCTTGCTGCCAGATGGTTTGAGGCCAATAGGCCGACCCGCCGACT
L T I T E D V A R T A N L A I E L D S A
CTCACTATAACTGAGGATGTTGCACGGACAGCAATCTGGCCATCGAGCTTGACTCAGCC 2880
40 T D V G R A C A G C R V T P G V V Q Y Q
ACAGATGTGCGCCGGGCTGTGCCGGCTGTGGGTACACCCCGGCGTTGTTCACTACCAG
F T A G V P G S G K S R S I T Q A D V D
45 TTTACTGCAGGTGTGCTGGATCCGGCAAGTCCGCTCTATACCCAAGCCGATGTGGAC 3000
V V V V P T R E L R N A W R R R G F A A
GTTGTCGTGGTCCCGACGCGTGAGTTGCGTAATGCCTGGCGCGTTCGGGCTTTGCTGCT
F T P H T A A R V T Q G R R V V I D E A
50 TTTACCCCGCATACTGCCGCCAGAGTCACCCAGGGGCGCCGGGTTGTCATTGATGAGGCT 3120
P S L P P H L L L L H M Q R A A T V H L
CCATCCCTCCCCCTCACCTGCTGCTGCTCCACATGCAGCGGGGCCGCCACCGTCCACCTT
L G D P N Q I P A I D F E H A G L V P A
55 CTTGGCGACCCGAACCAGATCCAGCCATCGACTTTGAGCACGCTGGGCTCGTCCCCGCC 3240
I R P D L G P T S W W H V T H R W P A D
60 ATCAGGCCGACTTAGGCCCCACCTCCTGGTGGCATGTTACCCATCGCTGGCCTGCGGAT

00051410.001902

V C E L I R G A Y P M I Q T T S R V L R
GTATGCGAGCTCATCCGTGGTGCATACCCCATGATCCAGACCTAGCCGGGTTCTCCGT 3360
S L F W G E P A V G Q K L V F T Q A A K
5 TCGTTGTTCTGGGGTGAGCCTGCCGTGGGCAGAACTAGTGTTACCCAGGCGGCCAAG
P A N P G S V T V H E A Q G A T Y T E T
CCCGCCAACCCCGCTCAGTGACGGTCCACGAGGCGCAGGGCGCTACCTACACGGAGACC 3480
10 T I I A T A D A R G L I Q S S R A H A I
ACTATTATTGCCACAGCAGATGCCCGGGGCTTATTAGTCGTCTCGGGCTCATGCCATT
V A L T R H T E K C V I I D A P G L L R
GTTGCTCTGACGCGCCACACTGAGAAGTGGTCATATTGACGCACCAGGCCTGCTTCGC 3600
15 E V G I S D A I V N N F F L A G G E I G
GAGGTGGGCATCTCCGATGCAATCGTTAATAACTTTTTCTCGCTGGTGGCGAAATTGGT
H Q R P S V I P R G N P D A N V D T L A
20 CACCAAGCGCCCATCAGTTATTCCTGGCAACCTGACGCCAATGTTGACACCCTGGCT 3720
A F P P S C Q I S A F H Q L A E E L G H
GCCTTCCCGCGTCTTGCCAGATTAGTGCTTCCATCAGTTGGCTGAGGAGCTTGGCCAC
25 R P V P V A A V L P P C P E L E Q G L L
AGACCTGTCCCTGTTGCAGCTGTTCTACCACCCTGCCCGAGCTCGAACAGGGCCTTCTC 3840
Y L P Q E L T T C D S V V T F E L T D I
30 TACCTGCCCCAGGAGCTCACCACCTGTGATAGTGCGTAACATTTGAATTAACAGACATT
V H C R M A A P S Q R K A V L S T L V G
GTGCACTGCCGCATGGCCGCCCGAGCCAGCGCAAGGCCGTGCTGTCCACACTCGTGGGC 3960
35 R Y G G R T K L Y N A S H S D V R D S L
CGCTACGGCGGTGCGACAAAGCTCTACAATGCTTCCCACTCTGATGTTGCGGACTCTCTC
A R F I P A I G P V Q V T T C E L Y E L
GCCCGTTTTATCCCGGCCATTGGCCCCGTACAGGTTACAACCTTGTAATTGTACGAGCTA 4080
40 V E A M V E K G Q D G S A V L E L D L C
GTGGAGGCCATGGTCGAGAAGGGCCAGGATGGCTCCGCCGTCTTGAGCTTGATCTTTGC
N R D V S R I T F F Q K D C N K F T T G
45 AACCGTGACGTGTCCAGGATCACCTTCTTCCAGAAAGATTGTAACAAGTTACCCACAGGT 4200
E T I A H G K V G Q G I S A S K T F C
GAGACCATTGCCATGGTAAAGTGGGCCAGGGCATCTCGGCCTGGAGCAAGACCTTCTGC
A L F G P W F R A I E K A I L A L L P Q
50 GCCCTCTTTGGCCCTTGGTTCCGCGCTATTGAGAAGGCTATTCTGGCCCTGCTCCCTCAG 4320
G V F Y G D A F D D T V F S A A V A A A
GGTGTGTTTTACGGTGATGCCTTTGATGACACCGTCTTCTCGGCGGCTGTGGCCGACGA
55 K A S M V F E N D F S E F D S T Q N N F
AAGGCATCCATGGTGTGTTGAGAATGACTTTTCTGAGTTTGACTCCACCCAGAATAACTTT 4440
S L G L E C A I M E E C G M P Q W L I R
60 TCTCTGGGTCTAGAGTGTGCTATTATGGAGGAGTGTGGGATGCCGCAGTGGCTCATCCGC

L Y H L I R S A W I L Q A P K E S L R G
 CTGTATCACCTTATAAGGTCTGCGTGGATCTTGCCAGGCCCGAAGGAGTCTCTGCGAGGG 4560
 F W K K H S G E P G T L L W N T V W N M
 5 TTTTGAAGAAACACTCCGGTGAGCCCGCACTCTTCTATGGAATACTGTCTGGAATATG
 A V I T H C Y D F R D F Q V A A F K G D
 GCCGTTATTACCACTGTTATGACTTCCGCGATTTTCAGGTGGCTGCCTTTAAAGGTGAT 4680
 10 D S I V L C S E Y R Q S P G A A V L I A
 GATTGATAGTGCTTTGCACTGAGTATCGTCAGAGTCCAGGAGCTGTGTCTGATCGCC
 G C G L K L K V D F R P I G L Y A G V V
 GGCTGTGGCTTGAAGTTGAAGGTAGATTTCCGCCGATCGGTTGTATGCAGGTGTTGTG 4800
 15 V A P G L G A L P D V V R F A G R L T E
 GTGGCCCCCGCCTTGCGCGCTCCCTGATGTTGTGCGCTTCCGCCGCGGCTTACCGAG
 K N W G P G P E R A E Q L R L A V S D F
 20 AAGAATTGGGGCCCTGGCCCTGAGCGGGCGGAGCAGCTCCGCCTCGCTGTTAGTGATTTT 4920
 L R K L T N V A Q M C V D V V S R V Y G
 CTCCGCAAGCTCACGAATGTAGCTCAGATGTGTGGATGTTGTTTCCCGTGTATGGG
 25 V S P G L V H N L I G M L Q A V A D G K
 GTTTCCTGGAAGTCTGTTCAACCTGATTGGCATGCTACAGGCTGTTGCTGATGGCAAG 5040
 A H F T E S V K P V L D L T N S I L C R
 30 GCACATTTCACTGAGTCAGTAAAACAGTCTCGACTTGACAAATTCATCTGTGTGCG
 | -ORF3-->
 M N N M S F A A P M G S R P C A L G
 M R P R P
 35 V E Z | -ORF2-->
 GTGGAATGAATAACATGTCTTTTGTGCGCCCATGGGTTGCGACCATGCGCCCTCGGCC 5160
 L F C C C S S C F C L C C P R H R P V S
 I L L L L L M F L P M L P A P P P G Q P
 40 TATTTTGTGCTGCTCCTCATGTTTTTGCCTATGCTGCCCGCGCCACCGCCCGGTACGCC
 R L A A V V G G A A A V P A V V S G V T
 S G R R R G R R S G G S G G G F W G D R
 45 GTCTGGCCCGCGTCTGTTGGCGGCGCAGCGGCGGTTCCGGCGGTGGTTTCTGGGGTGACCG 5280
 G L I L S P S Q S P I F I Q P T P S P P
 V D S Q P F A I P Y I H P T N P F A P D
 50 GGTGATTCTCAGCCCTTCGCAATCCCTATATTCATCCAACCAACCCCTTCGCCCCGA
 M S P L R P G L D L V F A N P P D H S A
 V T A A A G A G P R V R Q P A R P L G S
 55 TGTCACCGCTGCGGCCGGGGCTGGACCTCGTGTTCGCCAACC CGCCGACCACTCGGCTC 5400

09851410-021902

P L G V T R P S A P P L P H V V D L P Q
A W R D Q A Q R P A V A S R R R P T T A
CGCTTGGCGTGACCAGGCCAGCGCCCGCGTTGCCTCACGTCGTAGACCTACCACAGC
5 L G P R R Z
G A A P L T A V A P A H D T P P V P D V
TGGGGCCGCGCCGCTAACCGCGGTCGCTCCGGCCCATGACACCCGCCAGTGCCTGATGT 5520
10 D S R G A I L R R Q Y N L S T S P L T S
CGACTCCCGCGCGCCATCTTGC CGCGG CAGTATAACCTATCAACATCTCCCTTACCTC
15 S V A T G T N L V L Y A A P L S P L L P
TTCCGTGGCCACCGGCACTAACCTGGTTCTTTATGCCGCCCTCTTAGTCCGCTTTTACC 5640
L Q D G T N T H I M A T E A S N Y A Q Y
20 CCTTCAGGACGGCACCAATACCCATATAATGGCCACGGAAGCTTCTAATTATGCCCAGTA
R V A R A T I R Y R P L V P N A V G G Y
25 CCGGGTTGCCCGTGCCACAATCCGTTACCGCCCGCTGGTCCCAATGCTGTGCGGCGTTA 5760
A I S I S F W P Q T T T T P T S V D M N
CGCCATCTCCATCTCATTCTGGCCACAGACCACCACCCCGACGTCCGTTGATATGAA
30 S I T S T D V R I L V Q P G I A S E L V
TTCAATAACCTCGACGGATGTTCTGATTTTAGTCCAGCCCGGCATAGCCTCTGAGCTTGT 5880
35 I P S E R L H Y R N Q G W R S V E T S G
GATCCCAAGTGAGCGCCTACACTATCGTAACCAAGGCTGGCGCTCCGTCGAGACCTCTGG
V A E E E A T S G L V M L C I H G S L V
40 GGTGGCTGAGGAGGAGGCTACCTCTGGTCTTGTATGCTTTGCATACATGGCTCACTCGT 6000
N S Y T N T P Y T G A L G L L D F A L E
45 AAATTCCTATACTAATACACCTATACCGGTGCCCTCGGGCTGTTGGACTTTGCCCTTGA
L E F R N L T P G N T N T R V S R Y S S
GCTTGAGTTTCGCAACCTTACCCCGGTAACACCAATACGCGGGTCTCCCGTTATTCCAG 6120
50 T A R H R L R R G A D G T A E L T T T A
CACTGCTCGCCACCGCCTTCGTGCGGTGCGGACGGGACTGCCGAGCTCACCACCACGGC
55 A T R F M K D L Y F T S T N G V G E I G
TGCTACCCGCTTTATGAAGGACCTCTATTTTACTAGTACTAATGGTGTCGGTGAGATCGG 6240

R G I A L T L F N L A D T L L G G L P T
 CCGCGGGATAGCCCTCACCTGTTCAACCTTGCTGACACTCTGCTTGGCGGCCTGCCGAC
 5 E L I S S A G G Q L F Y S R P V V S A N
 AGAATTGATTCGTCGGCTGGTGGCCAGCTGTTCTACTCCCGTCCCGTTGTCTCAGCCAA 6360
 G E P T V K L Y T S V E N A Q Q D K G I
 10 TGGCGAGCCGACTGTTAAGTTGTATACATCTGTAGAGAATGCTCAGCAGGATAAGGGTAT
 A I P H D I D L G E S R V V I Q D Y D N
 15 TGCAATCCCGCATGACATTGACCTCGGAGAATCTCGTGTGGTTATTGAGGATTATGATAA 6480
 Q H E Q D R P T P S P A P S R P F S V L
 CCAACATGAACAAGATCGGCCGACGCCTTCTCCAGCCCCATCGCGCCCTTTCTCTGCTCT
 20 R A N D V L W L S L T A A E Y D Q S T Y
 TCGAGCTAATGATGTGCTTTGGCTCTCTCTCACCGCTGCCGAGTATGACCAGTCCACTTA 6600
 25 G S S T G P V Y V S D S V T L V N V A T
 TGGCTCTTCGACTGGCCCAGTTTATGTTTCTGACTCTGTGACCTTGGTTAATGTTGCGAC
 G A Q A V A R S L D W T K V T L D G R P
 30 CGGCGCGCAGGCCGTTGCCCGGTGCTCGATTGGACCAAGGTCACACTTGACGGTCGCCC 6720
 L S T I Q Q Y S K T F F V L P L R G K L
 35 CCTCTCCACCATCCAGCAGTACTCGAAGACCTTCTTTGTCTGCGCTCCGCGGTAAGCT
 S F W E A G T T K A G Y P Y N Y N T T A
 CTCTTTCTGGGAGGCAGGCACAATAAGCCGGGTACCTTATAATTATAACACCACTGC 6840
 40 S D Q L L V E N A A G H R V A I S T Y T
 TAGCGACCAACTGCTTGTCGAGAATGCCGCCGGGCACCGGGTCGCTATTTCCACTTACAC
 45 T S L G A G P V S I S A V A V L A P H S
 CACTAGCCTGGGTGCTGGTCCCGTCTCCATTTCTGCGGTTGCCGTTTTAGCCCCCACTC 6960
 A L A L L E D T L D Y P A R A H T F D D
 50 TGCGCTAGCATTGCTTGAGGATACCTTGGAATACCTGCCCCGCGCCATACTTTTGATGA
 F C P E C R P L G L Q G C A F Q S T V A
 55 TTTCTGCCAGAGTGCCGCCCTTTGGCCTTCAGGGCTGCGCTTTCCAGTCTACTGTCGC 7080
 E L Q R L K M K V G K T R E L Z
 60 TGAGCTTCAGCGCCTTAAGATGAAGGTGGGTAAAACCTCGGGAGTTGTAGTTTATTTGCTT

5 Total number of bases in this sequence as presented is 7195. The poly-A tail present in the cloned sequence has been omitted.

10 The ability of the methods described herein to isolate and identify genetic material from other NANB hepatitis strains has been confirmed by identifying genetic material from an isolate obtained in Mexico. The sequence of this isolate was about 75% identical to the ET1.1 sequence set forth in SEQ ID NO.1 above. The sequence was identified by hybridization using the conditions set forth in Section II.B below.

15 In this different approach to isolation of the virus, cDNA libraries were made directly from a semi-purified human stool specimen collected from an outbreak of ET-NANB in Telixtac. The recovery of cDNA and the construction of representative libraries was assured by the application of sequence independent single premier amplification (SISPA). A cDNA library
20 constructed in lambda gtl1 from such an amplified cDNA population was screened with a serum considered to have "high" titer anti-HEV antibodies as assayed by direct immunofluorescence on liver sections from
25 infected cynos. Two cDNA clones, denoted 406.3-2 and 406.4-2, were identified by this approach from a total of 60,000 screened. The sequence of these clones was subsequently localized to the 3' half of the viral genome by homology comparison to the HEV (Burma)
30 sequence obtained from clones isolated by hybridization screening of libraries with the original ET1.1 clone.

35 These isolated cDNA epitopes when used as hybridization probes on Northern blots of RNA extracted from infected cyno liver gave a somewhat different result when compared to the Northern blots obtained with the ET1.1 probe. In addition to the single 7.5 Kb transcript seen using ET1.1, two

additional transcripts of 3.7 and 2.0 Kb were identified using either of these epitopes as hybridization probes. These polyadenylated transcripts were identified using the extreme 3' end epitope clone (406.3-2) as probe and therefore established these transcripts as co-terminal with the 3' end of the genome (see below). One of the epitope clones (406.4-2) was subsequently shown to react in a specific fashion with antisera collected from 5 different geographic epidemics (Somalia, Burma, Mexico, Tashkent and Pakistan). The 406.3-2 clone reacted with sera from 4 out of these same 5 epidemics (Yarborough et al., 1990). Both clones reacted with only post inoculation antisera from infected cynos. The latter experiment confirmed that seroconversion in experimentally infected cynos was related to the isolated exogenous cloned sequence.

A composite cDNA sequence (obtained from several clones of the Mexican strain) is set forth below. Composite Mexico strain sequence (SEQ ID NO.10):

SEQ ID NO. 10:

	GCCATGGAGG CCCACCAAGT CATTAAGGCT CCTGGCATCA CTACTGCTAT TGAGCAAGCA	60
25	GCTCTAGCAG CGGCCAACTC CGCCCTTGCG AATGCTGTGG TGGTCCGGCC TTTCTTTCC	120
	CATCAGCAGG TTGAGATCCT TATAAATCTC ATGCAACCTC GGCAGCTGGT GTTTCGTCCT	180
30	GAGGTTTTTT GGAATCACCC GATTCAACGT GTTATACATA ATGAGCTTGA GCAGTATTGC	240
	CGTGCTCGCT CGGGTCGCTG CCTTGAGATT GGAGCCCACC CACGCTCCAT TAATGATAAT	300
	CCTAATGTCC TCCATCGCTG CTTTCTCCAC CCCGTCGGCC GGGATGTTCA GCGCTGGTAC	360
35	ACAGCCCCGA CTAGGGGACC TGCGGCGAAC TGTCGCCGCT CGGCACTTCG TGGTCTGCCA	420
	CCAGCCGACC GCACTTACTG TTTTGATGGC TTGCGCGGCT GCCGTTTTGC CGCCGAGACT	480
40	GGTGTGGCTC TCTATTCTCT CCATGACTTG CAGCCGGCTG ATGTTGCCGA GGCGATGGCT	540
	CGCCACGGCA TGACCCGCTT TTATGCAGCT TTCCACTTGC CTCCAGAGGT GTCCTGCCT	600
	CCTGGCACCT ACCGGACATC ATCCTACTTG CTGATCCACG ATGGTAAGCG CGCGGTTGTC	660
45	ACTTATGAGG GTGACACTAG CGCCGGTTAC AATCATGATG TTGCCACCCT CCGCACATGG	720

0951410.024902

	ATCAGGACAA CTAAGTTGT GGGTGAACAC CCTTTGGTGA TCGAGCGGGT GCGGGGTATT	780
	GGCTGTCACT TTGTGTTGTT GATCACTGCG GCCCCTGAGC CCTCCCCGAT GCCCTACGTT	840
5	CCTTACCCGC GTTCGACGGA GGTCTATGTC CGGTCTATCT TTGGGCCCGG CGGGTCCCCG	900
	TCGCTGTTCC CGACCGCTTG TGCTGTCAAG TCCACTTTTC ACGCCGTCCC CACGCACATC	960
	TGGGACCGTC TCATGCTCTT TGGGGCCACC CTCGACGACC AGGCCTTTTG CTGCTCCAGG	1020
10	CTTATGACGT ACCITCGTGG CATTAGCTAT AAGGTAAGTGGTGGTGCCTT GGTCGCTAAT	1080
	GAAGGCTGGA ATGCCACCGA GGATGCGCTC ACTGCAGTTA TTACGGCGGC TTACCTCACA	1140
15	ATATGTCATC AGCGTTATTT GCGGACCCAG GCGATTTCTA AGGGCATGCG CCGGCTTGAG	1200
	CTTGAACATG CTCAGAAATT TATTTACGCG CTCTACAGCT GGCTATTTGA GAAGTCAGGT	1260
	CGTGATTACA TCCCAGGCCG CCAGCTGCGC TTCTACGCTC AGTGCCGCCG CTGGTTATCT	1320
20	GCCGGGTTCC ATCTCGACCC CCGCACCTTA GTTTTTGATG AGTCAGTGCC TTGTAGCTGC	1380
	CGAACCACCA TCCGGCGGAT CGCTGGAAAA TTTTGCTGTT TTATGAAGTG GCTCGGTCAG	1440
25	GAGTGTCTT GTTTCCTCCA GCCCGCCGAG GGGCTGGCGG GCGACCAAGG TCATGACAA	1500
	GAGGCCTATG AAGGCTCTGA TGTTGATACT GCTGAGCCTG CCACCCTAGA CATTACAGGC	1560
	TCATACATCG TGGATGGTCG GTCTCTGCAA ACTGTCTATC AAGCTCTCGA CCTGCCAGCT	1620
30	GACCTGGTAG CTCGCGCAGC CCGACTGTCT GCTACAGTTA CTGTTACTGA AACCTCTGGC	1680
	CGTCTGGATT GCCAAACAAT GATCGGCAAT AAGACTTTTC TCACTACCTT TGTTGATGGG	1740
35	GCACGCCTTG AGGTTAACGG GCCTGAGCAG CTTAACCTCT CTTTGGACAG CCAGCAGTGT	1800
	AGTATGGCAG CCGGCCCGTT TTGCCTCACC TATGCTGCCG TAGATGGCGG GCTGGAAGTT	1860
	CATTTTTCCA CCGCTGGCCT CGAGAGCCGT GTTGTTTTCC CCCCTGGTAA TGCCCCGACT	1920
40	GCCCCGCCGA GTGAGGTCAC CGCCTTCTGC TCAGCTCTTT ATAGGCACAA CCGGCAGAGC	1980
	CAGCGCCAGT CGGTTATTGG TAGTTTGTGG CTGCACCTG AAGGTTTGCT CGGCCTGTTC	2040
45	CCGCCCTTTT CACCCGGGCA TGAGTGGCGG TCTGCTAACC CATTTTGGCG CGAGAGCAGC	2100
	CTCTACACCC GCACTTGGTC CACAATTACA GACACACCCT TAACTGTGCG GCTAATTTCC	2160
	GGTCATTTGG ATGCTGCTCC CCACTCGGGG GGGCCACCTG CTAAGTCCAC AGGCCTGTCT	2220
50	GTAGGCTCGT CTGACTCTCC AGACCCTGAC CCGCTACCTG ATGTTACAGA TGGCTCACGC	2280
	CCCTCTGGGG CCCGTCGGG TGGCCCCAAC CCGAATGGCG TTCCGCAGCG CCGCTTACTA	2340
55	CACACCTACC CTGACGGCGC TAAGATCTAT GTCGGCTCCA TTTTCGAGTC TGAGTGCACC	2400

09651410.021902

	TGGCTTGTC ACGCATCTAA CGCCGGCCAC CGCCCTGGTG GCGGGCTTTG TCATGCTTTT	2460
	TTTCAGCGTT ACCCTGATTC GTTTGACGCC ACCAAGTTTG TGATGCGTGA TGGTCTTGCC	2520
5	GCGTATACCC TTACACCCCG GCCGATCATT CATGCGGTGG CCCC GGACTA TCGATTGGAA	2580
	CATAACCCCA AGAGGCTCGA GGCTGCCTAC CGCGAGACTT GCGCCCGCGG AGGCACTGCT	2640
	GCCTATCCAC TCTTAGGCGC TGGCATTTAC CAGGTGCCTG TTAGTTTGAG TTTTGATGCC	2700
10	TGGGAGCGGA ACCACCGCCC GTTTGACGAG CTTTACCTAA CAGAGCTGGC GGCTCGGTGG	2760
	TTTGAATCCA ACCGCCCCGG TCAGCCCACG TTGAACATAA CTGAGGATAC CGCCCGTGCG	2820
15	GCCAACCTGG CCCTGGAGCT TGA CTCCGGG AGTGAAGTAG GCCGCGCATG TGCCGGGTGT	2880
	AAAGTCGAGC CTGGCGTTGT GCGGTATCAG TTTACAGCCG GTGTCCCCGG CTCTGGCAAG	2940
	TCAAAGTCGG TGCAACAGGC GGATGTGGAT GTTGTGTGTG TGCCCACTCG CGAGCTTCGG	3000
20	AACGCTTGGC GCGCGCGGG CTTTGCGGCA TTTACTCCGC AACTGCGGC CCGTGCTACT	3060
	AGCGGCCGTA GGGTTGTCAT TGATGAGGCC CTTTCGCTCC CCCCACACTT GCTGCTTTTA	3120
25	CATATGCAGC GTGCTGCATC TGTGCACCTC CTTGGGGACC CGAATCAGAT CCCC GCCATA	3180
	GATTTTGAGC ACACCGGTCT GATTCCAGCA ATACGGCCGG AGTTGGTCCC GACTTCATGG	3240
	TGGCATGTCA CCCACCGTTG CCCTGCAGAT GTCTGTGAGT TAGTCCGTGG TGCTTACCCT	3300
30	AAAATCCAGA CTACAAGTAA GGTGCTCCGT TCCCTTTTCT GGGGAGAGCC AGCTGTCCGC	3360
	CAGAAGCTAG TGTTACACA GGCTGCTAAG GCCGCGCACC CCGGATCTAT AACGGTCCAT	3420
35	GAGGCCCAGG GTGCCACTTT TACCACTACA ACTATAATTG CAACTGCAGA TGCCCGTGGC	3480
	CTCATACAGT CCTCCCGGGC TCACGCTATA GTTGCTCTCA CTAGGCATAC TGAAAAATGT	3540
	GTTATACTTG ACTCTCCCG CTTGTTGCGT GAGGTGGGTA TCTCAGATGC CATTGTTAAT	3600
40	AATTTCTTCC TTTGGGTGG CGAGGTTGGT CACCAGAGAC CATCGGTCAT TCCGCGAGGC	3660
	AACCTGACC GCAATGTTGA CGTGCTTGGC GCGTTTCCAC CTTATGCCA AATAAGCGCC	3720
45	TTCCATCAGC TTGCTGAGGA GCTGGGCCAC CGGCCGGCGC CGGTGGCGGC TGTGCTACCT	3780
	CCCTGCCCTG AGCTTGAGCA GGGCCTTCTC TATCTGCCAC AGGAGCTAGC CTCCTGTGAC	3840
	AGTGTTGTGA CATTTGAGCT AACTGACATT GTGCACTGCC GCATGGCGGC CCCTAGCCAA	3900
50	AGGAAAGCTG TTTTGTCCAC GCTGGTAGGC CGGTATGGCA GACGCACAAG GCTTTATGAT	3960
	GCGGGTCACA CCGATGTCCG CGCTCCCTT GCGCGCTTTA TTCCCACTCT CGGGCGGGTT	4020
55	ACTGCCACCA CCTGTGAACT CTTTGAGCTT GTAGAGGCGA TGGTGAGAA GGGCCAAGAC	4080

09651410.021902

	GGTTCAGCCG TCCTCGAGTT GGATTTGTGC AGCCGAGATG TCTCCGCGAT AACCTTTTTT	4140
	CAGAAGGATT GTAACAAGTT CACGACCGGC GAGACAATTG CGCATGGCAA AGTCGGTCAG	4200
5	GGTATCTCC GCTGGAGTAA GACGTTTTGT GCCCTGTTG GCCCTGGTT CCGTGCGATT	4260
	GAGAAGGCTA TTCTATCCCT TTTACCACAA GCTGTGTTCT ACGGGGATGC TTATGACGAC	4320
10	TCAGTATTCT CTGCTGCCGT GGCTGGCGCC AGCCATGCCA TGGTGTGGA AAATGATTTT	4380
	TCTGAGTTTG ACTCGACTCA GAATAACTTT TCCCTAGGTC TTGAGTGCGC CATTATGGAA	4440
	GAGTGTGGTA TGCCCCAGTG GCTTGTCAGG TTGTACCATG CCGTCCGGTC GCGTGGATC	4500
15	CTGCAGGCC CAAAAGAGTC TTTGAGAGGG TTCTGGAAGA AGCATTCTGG TGAGCCGGGC	4560
	AGCTTGCTCT GGAATACGGT GTGGAACATG GCAATCATTG CCCATTGCTA TGAGTTCCGG	4620
20	GACCTCCAGG TTGCCGCTT CAAGGGCGAC GACTCGGTG TCCTCTGTAG TGAATACCGC	4680
	CAGAGCCCAG GCGCCGGTTC GCTTATAGCA GGCTGTGGT TGAAGTTGAA GGCTGACTTC	4740
	CGGCCGATTG GGCTGTATGC CGGGTTGTC GTCGCCCCGG GGCTCGGGC CCTACCCGAT	4800
25	GTCGTTGAT TCGCCGACG GCTTTCGGAG AAGAACTGGG GGCCTGATCC GGAGCGGGCA	4860
	GAGCAGCTCC GCCTGCGGT GCAGGATTC CTCGTAAGT TAACGAATGT GGCCAGATT	4920
30	TGTGTTGAGG TGGTGTCTAG AGTTTACGGG GTTTCCCCGG GTCTGGTTCA TAACCTGATA	4980
	GGCATGCTCC AGACTATTGG TGATGGTAAG GCGCATTTTA CAGAGTCTGT TAAGCCTATA	5040
	CTTGACCTTA CACACTCAAT TATGCACCG TCTGAATGAA TAACATGTGG TTTGCTGCGC	5100
35	CCATGGGTTG GCCACCATGC GCCCTAGGCC TCTTTTGCTG TTGTTCTCT TGTTCCTGCC	5160
	TATGTTGCCC GCGCCACCGA CCGGTCAGCC GTCTGGCCGC CGTCGTGGGC GCGCAGCGG	5220
40	CGGTACCGGC GGTGGTTTCT GGGGTGACCG GGTGATTCT CAGCCCTTCG CAATCCCCTA	5280
	TATTCATCCA ACCAACCCT TTGCCCCAGA CGTTGCCGCT GCGTCCGGT CTGGACCTCG	5340
	CCTTCGCCAA CCAGCCCGGC CACTTGCTC CACTTGGCGA GATCAGGCC AGCGCCCTC	5400
45	CGCTGCCTCC CGTCGCCGAC CTGCCACAGC CGGGGCTGCG GCGCTGACGG CTGTGGCGCC	5460
	TGCCCATGAC ACCTCACCG TCCCGACGT TGATTCTCG GGTGCAATC TACGCCCCA	5520
50	GTATAATTG TCTACTTAC CCCTGACATC CTCTGTGGC TCTGGCACTA ATTAGTCTT	5580
	GTATGCAGCC CCCCTTAATC CGCTCTGCC GCTGCAGGAC GGTACTAATA CTCACATTAT	5640
	GGCCACAGAG GCCTCCAATT ATGCACAGTA CCGGGTTGCC GCGCTACTA TCCGTTACCG	5700
55	GCCCCTAGTG CCTAATGCAG TTGGAGGCTA TGCTATATCC ATTCTTTCT GGCTCAAAAC	5760

	AACCACAACC CCTACATCTG TTGACATGAA TTCCATTACT TCCACTGATG TCAGGATTCT	5820
	TGTTCAACCT GGCATAGCAT CTGAATTGGT CATCCCAAGC GAGCGCCTTC ACTACCGCAA	5880
5	TCAAGGTTGG CGCTCGGTTG AGACATCTGG TGTGCTGAG GAGGAAGCCA CCTCCGGTCT	5940
	TGTCATGTTA TGCATACATG GCTCTCCAGT TAACTCCTAT ACCAATACCC CTTATACCGG	6000
	TGCCCTTGGC TTAGTGACT TTGCCITAGA GCTTGAGTTT CGCAATCTCA CCACCTGTAA	6060
10	CACCAATACA CGTGTGTCCC GTTACTCCAG CACTGCTCGT CACTCCGCCC GAGGGGCCGA	6120
	CGGGACTGCG GAGCTGACCA CAACTGCAGC CACCAGGTTC ATGAAAGATC TCCACTTTAC	6180
15	CGGCCTTAAT GGGGTAGGTG AAGTCGGCCG CGGGATAGCT CTAACATTAC TTAACCTTGC	6240
	TGACACGCTC CTCGGCGGGC TCCCGACAGA ATTAATTTTC TCGGCTGGCG GGCAACTGTT	6300
	TTATTCCCGC CCGGTTGTCT CAGCCAATGG CGAGCCAACC GTGAAGCTCT ATACATCAGT	6360
20	GGAGAATGCT CAGCAGGATA AGGGTGTTC TATCCCCAC GATATCGATC TTGGTGATTC	6420
	GCGTGTGGTC ATTCAGGATT ATGACAACCA GCATGAGCAG GATCGGCCCA CCCCCTCGCC	6480
25	TGCGCCATCT CGGCCTTTTT CTGTTCTCG AGCAAATGAT GTACTTTGGC TGTCCTCAC	6540
	TGCAGCCGAG TATGACCAGT CCACTTACGG GTCGTCAACT GGCCCGGTTT ATATCTCGGA	6600
	CAGCGTGAAT TTGGTGAATG TTGCGACTGG CGCGCAGGCC GTAGCCCGAT CGCTTGACTG	6660
30	GTCCAAAGTC ACCCTCGACG GCGGCCCCCT CCCGACTGTT GAGCAATATT CCAAGACATT	6720
	CTTTGTGCTC CCCCTTCGTG GCAAGCTCTC CTTTGGGAG GCCGGCACAA CAAAGCAGG	6780
35	TTATCCTTAT AATTATAATA CTAAGCTAG TGACCAGATT CTGATTGAAA ATGCTGCCGG	6840
	CCATCGGGTC GCCATTTCAA CCTATACCAC CAGGCTTGGG GCCGGTCCGG TCGCCATTTT	6900
	TGCGGCCGCG GTTTTGGCTC CACGCTCCGC CCTGGCTCTG CTGGAGGATA CTTTTGATTA	6960
40	TCCGGGGCGG GCGCACACAT TTGATGACTT CTGCCCTGAA TGCCGCGCTT TAGGCCTCCA	7020
	GGGTTGTGCT TTCCAGTCAA CTGTCGCTGA GCTCCAGCGC CTAAAGTTA AGGTGGGTAA	7080
45	AACTCGGGAG TTGTAGTTTA TTTGGCTGTG CCCACCTACT TATATCTGCT GATTTCCTTT	7140
	ATTTCTTTT TCTCGGTCCC GCGCTCCCTG A	7171

50 The above sequence was obtained from
polyadenylated clones. For clarity the 3' polyA
"tail" has been omitted.

0951410-021504

The sequence above includes a partial cDNA sequence consisting of 1661 nucleotides that was identified in a previous application in this series. The previously identified partial sequence is set forth below, with certain corrections (SEQ ID NO.11). The corrections include deletion of the first 80 bases of the prior reported sequence, which are cloning artifacts; insertion of G after former position 174, of C after 270, and of GGCG after 279; change of C to T at former position 709, of GC to CG at 722-723, of CC to TT at 1238-39, and of C to G at 1606; deletion of T at former position 765; and deletion of the last 11 bases of the former sequence, which are part of a linker sequence and are not of viral origin.

15 Non-A Non-B T: Mexican Strain; SEQ ID NO.11
SEQ ID NO. 11:

	GTTGCGTGAG GTGGGTATCT CAGATGCCAT TGTTAATAAT TTCTTCCTTT CGGGTGCGCA	60
20	GGTTGGTCAC CAGAGACCAT CGGTCATTCC GCGAGGCAAC CCTGACCGCA ATGTTGACGT	120
	GCTTGCGGCG TTTCCACCTT CATGCCAAAT AAGCGCCTTC CATCAGCTTG CTGAGGAGCT	180
	GGGCCACCGG CCGGCGCCGG TGGCGGCTGT GCTACCTCCC TGCCCTGAGC TTGAGCAGGG	240
25	CCTTCTCTAT CTGCCACAGG AGCTAGCCTC CTGTGACAGT GTTGTGACAT TTGAGCTAAC	300
	TGACATTGTG CACTGCCGCA TGGCGGCCCC TAGCCAAAGG AAAGCTGTTT TGTCCACGCT	360
30	GGTAGGCCGG TATGGCAGAC GCACAAGGCT TTATGATGCG GGTACACCG ATGTCCGCGC	420
	CTCCCTTGCG CGCTTTATTC CCACTCTCGG GCGGGTTACT GCCACCACCT GTGAACTCTT	480
	TGAGCTTGTA GAGGCGATGG TGGAGAAGGG CCAAGACGGT TCAGCCGTCC TCGAGTTGGA	540
35	TTTGTGCAGC CGAGATGTCT CCCGCATAAC CTTTTTCCAG AAGGATTGTA ACAAGTTCAC	600
	GACCGGCGAG ACAATTGCGC ATGGCAAAGT CGGTCAGGGT ATCTTCGCT GGAGTAAGAC	660
40	CTTTGTGCC CTGTTTGCC CCTGGTTCG TCGATTGAG AAGGCTATTC TATCCCTTTT	720
	ACCACAAGCT GTGTTCTACG GGGATGCTTA TGACGACTCA GTATTCTCTG CTGCCGTGGC	780
	TGGCGCAGC CATGCCATGG TGTGAAAA TGATTTTCT GAGTTTGA CTGACTCAGAA	840
45	TAACCTTTCC CTAGGTCTTG AGTGCGCCAT TATGGAAGAG TGTGGTATGC CCCAGTGGCT	900
	TGTCAGGTTG TACCATGCCG TCCGGTCGGC GTGGATCCTG CAGGCCCAA AAGAGTCTTT	960

GAGAGGGTTC TGGAAGAAGC ATTCTGGTGA GCCGGGCACG TTGCTCTGGA ATACGGTGTG 1020
 GAACATGGCA ATCATTGCCC ATTGCTATGA GTTCCGGGAC CTCCAGGTTG CCGCCTTCAA 1080
 5 GGGCGACGAC TCGGTCGTCC TCTGTAGTGA ATACCGCCAG AGCCCAGGCG CCGGTTGCT 1140
 TATAGCAGGC TGTGGTTTGA AGTTGAAGGC TGACTTCCGG CCGATTGGGC TGTATGCCGG 1200
 GGTGTGTCGTC GCCCGGGGGC TCGGGGCCCT ACCCGATGTC GTTCGATTG CCGGACGGCT 1260
 10 TTCGGAGAAG AACTGGGGGC CTGATCCGGA GCGGGCAGAG CAGCTCCGCC TCGCCGTGCA 1320
 GGATTTCTC CGTAGGTTAA CGAATGTGGC CCAGATTTGT GTTGAGGTGG TGTCTAGAGT 1380
 15 TTACGGGGTT TCCCCGGGTC TGGTTCATAA CCTGATAGGC ATGCTCCAGA CTATTGGTGA 1440
 TGGTAAGGCG CATTTTACAG AGTCTGTAA GCCTATACTT GACCTTACAC ACTCAATTAT 1500
 GCACCGGTCT GAATGAATAA CATGTGGTTT GCTGCGCCCA TGGGTTCCGC ACCATGCGCC 1560
 20 CTAGGCCTCT TTTGC 1575

25 When comparing the Burmese and Mexican strains, 75.7% identity is seen in a 7189 nucleotide overlap beginning at nucleotide 1 of the Mexican strain and nucleotide 25 of the Burmese strain.

30 In the same manner, a different strain of HEV was identified in an isolate obtained in Tashkent, U.S.S.R. The Tashkent sequence is given below (SEQ ID NO.12):

SEQ ID NO. 12:

35 CGGGCCCCGT ACAGGTCACA ACCTGTGAGT TGTACGAGCT AGTGGAGGCC ATGGTCGAGA 60
 AAGGCCAGGA TGGCTCCGCC GTCCTTGAGC TCGATCTCTG CAACCGTGAC GTGTCCAGGA 120
 TCACCTTTT CCAGAAAGAT TGCAATAAGT TCACCACGGG AGAGACCATC GCCCATGGTA 180
 40 AAGTGGGCCA GGGCATTTCG GCCTGGAGTA AGACCTTCTG TGCCCTTTTC GGCCCTGGT 240
 TCCGTGCTAT TGAGAAGGCT ATTCTGGCCC TGCTCCCTCA GGGTGTGTTT TATGGGGATG 300
 CCTTTGATGA CACCGTCTTC TCGGCGCGTG TGGCCGCAGC AAAGGCGTCC ATGGTGTGTTG 360
 45 AGAATGACTT TTCTGAGTTT GACTCCACCC AGAATAATTT TTCCCTGGGC CTAGAGTGTG 420
 CTATTATGGA GAAGTGTGGG ATGCCGAAGT GGCTCATCCG CTTGTACCAC CTTATAAGGT 480
 50 CTGCGTGGAT CCTGCAGGCC CCGAAGGAGT CCCTGCGAGG GTGTTGGAAG AAACACTCCG 540
 GTGAGCCCGG CACTCTTCTA TGGAATACTG TCTGGAACAT GGCCGTTATC ACCCATGTGT 600

ACGATTTCCG CGATTTGCAG GTGGCTGCCT TTAAAGGTGA TGATTCGATA GTGCTTTGCA 660
 GTGAGTACCG TCAGAGTCCA GGGGCTGCTG TCCTGATTGC TGGCTGTGGC TTAAAGCTGA 720
 5 AGGTGGGTTT CCGTCCGATT GGTGTGTATG CAGGTGTTGT GGTGACCCCC GGCCTTGCGC 780
 CGCTTCCCGA CGTCGTGCGC TTGTCCGGCC GGCTTACTGA GAAGAATTGG GGCCCTGGCC 840
 10 CTGAGCGGGC GGAGCAGCTC CGCCTTGCTG TGGC 874

As shown in the following comparison of sequences, the Tashkent (Tash.) sequence more closely resembles the Burma sequence than the Mexico sequence, as would be expected of two strains from more closely related geographical areas. The numbering system used in the comparison is based on the Burma sequence. As indicated previously, Burma has SEQ ID NO:6; Mexico, SEQ ID NO:10; and Tashkent, SEQ ID NO:12. The letters present in the lines between the sequences indicate conserved nucleotides.

		10v	20v	30v	40v	50v	60v
25	-BURMA	AGGCAGACCACATATGTGGT	CGATGCCATGGAGGCCCATCAGTTTATTAAGGCTCCTGGCA				
				GCCATGGAGGCCCA	CAGTT	ATTAAGGCTCCTGGCA	
	-MEXICO			GCCATGGAGGCCCA	CACAGTT	CATTAAGGCTCCTGGCA	
		70v	80v	90v	100v	110v	120v
30	-BURMA	TCCTACTGCTATTGAGCAGGCTGCTCTAGCAGCGGCAACTCTGCCCTGGCGAATGCTG					
		TCCTACTGCTATTGAGCA	GC	GCTCTAGCAGCGGCAACTC	GCCCT	GCGAATGCTG	
	-MEXICO	TCCTACTGCTATTGAGCAAGCAGCTCTAGCAGCGGCAACTCCGCCCTTGGCGAATGCTG					
		130v	140v	150v	160v	170v	180v
35	-BURMA	TGGTAGTTAGGCCTTTTCTCTCTCACCAGCAGATTGAGATCCTCATTAACTAATGCAAC					
		TGGT GT	GGCCTT CT TC CA	CAGCAG	TTGAGATCCT	AT AA CT	ATGCAAC
	-MEXICO	TGGTGGTCCGGCCTTTCTTTCCCATCAGCAGTTGAGATCCTTATAAATCTCATGCAAC					
		190v	200v	210v	220v	230v	240v
40	-BURMA	CTCGCCAGCTTGTTTTCCGCCCGAGGTTTTCTGGAATCATCCCATCCAGCGTGTCTATCC					
		CTCG	CAGCT GT TT CG CC	GAGGTTTT	TGGAATCA	CC AT CA	CGTGT AT C
	-MEXICO	CTCGGCAGCTGGTGTTCGTCTGAGGTTTTTGGGAATCACCCGATTCAACGTGTTATAC					
		250v	260v	270v	280v	290v	300v
45	-BURMA	ATAACGAGCTGGAGCTTTACTGCCGCGCCGCTCCGCGCGCTGTCTTGAAATTGGCGCCC					
		ATAA	GAGCT GAGC	TA TGCCG	GC CGCTC	GG CGCTG	CTTGA ATTGG GCCC
	-MEXICO	ATAATGAGCTTGAGCAGTATTGCCGTCTCGCTCGGGTCTGCTTGAATTGAGAGCCC					
		310v	320v	330v	340v	350v	360v
50	-BURMA	ATCCCCGCTCAATAAATGATAATCCTAATGTGGTCCACCGCTGCTTCTCCGCCCTGTTG					
		A CC	CGCTC AT AATGATAATCCTAATGT	TCCA	CGCTGCTT	CTCC CCC	GT G
	-MEXICO	ACCCACGCTCCATTAATGATAATCCTAATGTCTCCATCGCTGCTTTCTCCACCCCGCTG					

0951410.061503

		370v	380v	390v	400v	410v	420v
	-BURMA	GGCGTGATGTTTCAGCGCTGGT-TACTGCTCCCACTCGCGGGCCGGCTGCTAATTGCCGGC					
5	-MEXICO	G CG GATGTTTCAGCGCTGGTA AG GC CC ACT G GG CC GC GC AA TG CG C GCCGGGATGTTTCAGCGCTGGTACAGCCCGACTAGGGGACCTGCGGCGAACTGTCGCC					
		430v	440v	450v	460v	470v	480v
	-BURMA	GTTCCGCGCTGCGCGGGCTTCCCGCTGCTGACCGCACTTACTGCCTCGACGGGTTTTCTG					
10	-MEXICO	G TC GC CT CG GG CT CC C GC GACCGCACTTACTG T GA GG TTT C G GCTCGGCACTTCGTGGTCTGCCACGAGCGGACCGCACTTACTGTTTTGATGGCTTTGCCG					
		490v	500v	510v	520v	530v	540v
	-BURMA	GCTGTAACITTTCCCGCCGAGACTGGCATCGCCCTCTACTCCCTTCATGATATGTCACCAT					
15	-MEXICO	GCTG TTT CCGCCGAGACTGG T GC CTCTA TC CT CATGA TG CC GCTGCCGTTTTGCCCGCAGACTGGTGTGGCTCTATTCTCTCCATGACTTGCAGCCGG					
		550v	560v	570v	580v	590v	600v
	-BURMA	CTGATGTGCGCGAGGCCATGTTCCGCCATGGTATGACGCGGCTCTATGCCGCCCTCCATC					
20	-MEXICO	CTGATGT GCCGAGGC ATG CGCCA GG ATGAC CG CT TATGC GC TCCA CTGATGTTGCCGAGGCGATGGCTCGCCACGGCATGACCCGCCCTTATGCAGCTTTCCACT					
		610v	620v	630v	640v	650v	660v
	-BURMA	TTCCGCCTGAGGTCTGCTGCCCCCTGGCACATATCGACCGCATCGTATTTGCTAATTC					
25	-MEXICO	T CC CC GAGGT CT CTGCC CCGGCAC TA CG AC CATC TA TTGCT AT C TGCTCCAGAGGTGCTCCTGCTCCTGGCACCTACCGGACATCATCCTACTTGCTGATCC					
		670v	680v	690v	700v	710v	720v
	-BURMA	ATGACGGTAGGCGCGTTGTGGTGACGTATGAGGGTGATACTAGTGCTGGTTACAACCACG					
30	-MEXICO	A GA GGTG GCGCG GT GT AC TATGAGGGTGA ACTAG GC GGTTACAA CA G ACGATGGTAAGCGCGCGGTTGTCACTTATGAGGGTGACACTAGCGCCGGTTACAATCATG					
		730v	740v	750v	760v	770v	780v
	-BURMA	ATGTCTCCAACITTCGCTCCTGGATTAGAACCAACAGGTTACCGGAGACCATCCCCCTCG					
35	-MEXICO	ATGT CCA C T CGC C TGGAT AG AC AC AAGGTT GG GA CA CC T G ATGTTGCCACCTCCGCGACATGGATCAGGACAACAAAGGTTGTGGGTGAACACCCCTTTGG					
		790v	800v	810v	820v	830v	840v
	-BURMA	TTATCGAGCGGGTTAGGGCCATTGGCTGCCACTTTGTTCTTGTCTACGGCAGCCCCGG					
40	-MEXICO	T ATCGAGCGGGT GGG ATTGGCTG CACTTTGT T TTG TCAC GC GCCCC G TGATCGAGCGGGTGCGGGGATTGGCTGTCACTTTGTGTTGTGATCACTGCGGCCCTG					
		850v	860v	870v	880v	890v	900v
	-BURMA	AGCCATCACCTATGCCITATGTTCTTACCCCGGTCTACCGAGGTCTATGTCCGATCGA					
45	-MEXICO	AGCC TC CC ATGCC TA GTTCTTACCC CG TC AC GAGGTCTATGTCCG TC A AGCCCTCCCCGATGCCCTACGTTCTTACCCGCGTTCGACGGAGGTCTATGTCCGGTCTA					
		910v	920v	930v	940v	950v	960v
	-BURMA	TCTTCGGCCCGGGTGGCACCCCTTCTTATTTCCCAACCTCATGCTCCACTAAGTCGACCT					
50	-MEXICO	TCTT GG CC GG GG CCCC TC T TTCCC ACC C TG C AAGTC AC T TCTTTGGGCCCGCGGGTCCCGCTGCTGTTCCCGACCGCTTGTGCTGTCAAGTCCACTT					
		970v	980v	990v	1000v	1010v	1020v
	-BURMA	TCCATGCTGTCCCTGCCCATATTTGGGACCGTCTTATGCTGTTTCGGGGCCACCTTGGATG					
55	-MEXICO	T CA GC GTCCC C CA AT TGGGACCGTCT ATGCT TT GGGGCCACC T GA G TTCACGCGGTCCCCACGGCATCTGGGACCGTCTCATGCTCTTTGGGGCCACCTCGACG					

0951410.021902

		1030v	1040v	1050v	1060v	1070v	1080v
	-BURMA	ACCAAGCCTTTTGTCTGCCGTTTAAATGACCTACCTTCGCGGCATTAGCTACAAGGTCA					
5	-MEXICO	ACCA GCCTTTTGTCTGCC G T ATGAC TACCTTCG GGCATTAGCTA AAGGT A ACCAGGCCTTTTGTCTGCCAGGCTTATGACGTACCTTCGTGGCATTAGCTATAAGGTAA					
		1090v	1100v	1110v	1120v	1130v	1140v
	-BURMA	CTGTTGGTACCCTTGTGGCTAATGAAGGCTGGAATGCCTCTGAGGACGCCCTCACAGCTG					
10	-MEXICO	CTGT GGT CCCT GT GCTAATGAAGGCTGGAATGCC C GAGGA GC CTCAC GC G CTGTGGGTGCCCTGGTCGCTAATGAAGGCTGGAATGCCACCGAGGATGCGCTCACTGCAG					
		1150v	1160v	1170v	1180v	1190v	1200v
	-BURMA	TTATCACTGCCGCTACCTTACCATTGGCCACCAGCGGTATCTCCGACCCAGGCTATAT					
15	-MEXICO	TTAT AC GC GC TACCT AC AT TG CA CAGCG TAT T CG ACCCAGGC AT T TTATTACGGCGGCTTACCTCACAATATGTCATCAGCGTTATTTGCGGACCCAGGCGATT					
		1210v	1220v	1230v	1240v	1250v	1260v
	-BURMA	CCAAGGGGATGCGTCTGGAACGGGAGCATGCCCAGAAGTTTATAACACGCCTCTACA					
20	-MEXICO	C AAGGG ATGCG CG CT GA C GA CATGC CAGAA TTTAT CACGCCTCTACA CTAAGGGCATGCCCGGCTTGAGCTTGAACATGCTCAGAAATTTATTTACGCCTCTACA					
		1270v	1280v	1290v	1300v	1310v	1320v
	-BURMA	GCTGGCTCTTCGAGAAGTCCGGCGTGATTACATCCCTGGCCGTCAGTTGGAGTTCTACG					
25	-MEXICO	GCTGGCT TT GAGAAGTC GG CGTGATTACATCCC GGCCG CAG TG AGTTCTACG GCTGGCTATTTGAGAAGTCAGGTCGTGATTACATCCAGGCCGCCAGCTGCAGTTCTACG					
		1330v	1340v	1350v	1360v	1370v	1380v
	-BURMA	CCAGTGACGGCGCTGGCTCTCCGCGGCTTTCATCTTGATCCACGGGTGTTGGTTTTTG					
30	-MEXICO	C CAGTGC G CGCTGG T TC GCCGG TT CATCT GA CC CG TT GTTTTTG CTCAGTGCCGCCGCTGGTTATCTGCCGGTTCCATCTCGACCCCGCACCTTAGTTTTTG					
		1390v	1400v	1410v	1420v	1430v	1440v
	-BURMA	ACGAGTCGGCCCCCTGCCATTGTAGGACCGCATCCGTAAGGCGCTCTCAAAGTTTTGCT					
35	-MEXICO	A GAGTC G CC TG TG G ACC C ATCCG G AAA TTTTGCT ATGAGTCAGTGCCTTGTAGCTGCCGAACCACCATCCGGCGGATCGTGGAATAATTTTGCT					
		1450v	1460v	1470v	1480v	1490v	1500v
	-BURMA	GCTTCATGAAGTGGCTTGGTCAGGAGTGACCTGCTTCCTTCAGCCTGCAGAAGGCCGCCG					
40	-MEXICO	G TT ATGAAGTGGCT GGTGAGGAGTG C TG TTCCT CAGCC GC GA GG G GTTTTATGAAGTGGCTCGGTGAGGAGTGTTCTTGTTCCTCCAGCCCGCCGAGGGGCTGG					
		1510v	1520v	1530v	1540v	1550v	1560v
	-BURMA	TCGGCGACCAAGGTCATGATAATGAAGCCTATGAGGGGTCCGATGTTGACCTGCTGAGT					
45	-MEXICO	GGCGACCA GGTCATGA AATGA GCCTATGA GG TC GATGTTGA CTGCTGAG CGGGCGACCAAGGTCATGACAATGAGGCCTATGAAGGCTCTGATGTTGATACTGCTGAGC					
		1570v	1580v	1590v	1600v	1610v	1620v
	-BURMA	CCGCCATTAGTGACATATCTGGGTCCTATGTCGTCCCTGGCACTGCCCTCCAACCGCTCT					
50	-MEXICO	C GCCA GACAT C GG TC TA TCGT TGG C CT CAA C TCT CTGCCACCCTAGACATTACAGGCTCATACATCGTGGATGGTCGGTCTCTGCAAACTGTCT					
		1630v	1640v	1650v	1660v	1670v	1680v
	-BURMA	ACCAGGCCCTCGATCTCCCGCTGAGATTGTGGCTCGCGCGGGCCGCTGACCGCCACAG					
55	-MEXICO	A CA GC CTCGA CT CC GCTGA T GT GCTCGCGC G CCG CTG C GC ACAG ATCAAGCTCTCGACCTGCCAGCTGACCTGGTAGCTCGCGCAGCCCGACTGTCTGCTACAG					

		1690v	1700v	1710v	1720v	1730v	1740v
	-BURMA	TAAAGGTCTCCAGGTCGATGGGCGGATCGATTGCGAGACCCCTTCTTGGTAACAAAACCT					
5	-MEXICO	T A GT C A C TGG CG T GATTGC A AC T T GG AA AA AC T					
		1750v	1760v	1770v	1780v	1790v	1800v
	-BURMA	TTGCGACGTCGTTTCGTTGACGGGGCGGCTTTAGAGACCAATGGCCCAGAGCGCCACAATC					
10	-MEXICO	TTC CAC C TT GTTGA GGGGC C T GAG AA GG CC GAGC C AA C					
		1810v	1820v	1830v	1840v	1850v	1860v
	-BURMA	TCTCCTTCGATGCCAGTCAGAGCACTATGGCCGCTGGCCCTTTCAGTCTCACCTATGCCG					
15	-MEXICO	TCTC TT GA C CAG G A TATGGC GC GGCC TT G CTCACCTATGC G					
		1870v	1880v	1890v	1900v	1910v	1920v
	-BURMA	CCTCTGCAGCTGGGCTGGAGGTGCGCTATGTTGCTGCCGGGCTTGACCATCGGGCGGTTT					
20	-MEXICO	CC G G GGGCTGGA GT C T T C GC GG CT GA CG G GTT					
		1930v	1940v	1950v	1960v	1970v	1980v
	-BURMA	TTGCCCCCGGTGTTTACCCCGGTGAGCCCCGCGAGGTTACCGCCTTCTGCTGCCCC					
25	-MEXICO	T CCCC GGT T C CC C C CC G GAGGT ACCGCCTTCTGCTC GC C					
		1990v	2000v	2010v	2020v	2030v	2040v
	-BURMA	TATACAGGTTTAAACCGTGAGGCCAGCGCCATTGCTGATCGGTAACCTATGTTCCATC					
30	-MEXICO	T TA AGG AACCG AG CCAGCGCCA TCG T AT GGTA TT TGG T CA C					
		2050v	2060v	2070v	2080v	2090v	2100v
	-BURMA	CTGAGGGACTCATTGGCCTCTTCGCCCCGTTTTGCCCCGGGCATGTTTGGGAGTCGGCTA					
35	-MEXICO	CTGA GG T T GGCCT TTC C CC TTTTC CCGGGCATG TGG GTC GCTA					
		2110v	2120v	2130v	2140v	2150v	2160v
	-BURMA	ATCCATTCTGTGGCGAGAGCACACCTTTACACCCGTAAGTGGTGGAGGTTGATGCCGTCT					
40	-MEXICO	A CCATT TG GGCAGAGCAC CT TACACCCG ACTTGGTC TT G C					
		2170v	2180v	2190v	2200v	2210v	2220v
	-BURMA	CTAGTCCAGCCCGGCTGACTTAGGTTTTATGTCTGAGCCTTCTATACCTAGTAGGGCCG					
45	-MEXICO	C C G C GGC T GGT T TG TG CT C C G GG C					
		2230v	2240v	2250v	2260v	2270v	2280v
	-BURMA	CCACGCCTACCCTGGCGGCCCTCTACCCCCCTGACCCGACCCCTTCCCCCCTCCCT					
50	-MEXICO	C C CT CC G C CT TA C C CTG C C CCC C					
		2290v	2300v	2310v	2320v	2330v	2340v
	-BURMA	CTGCCCCGGCGCTTGTGAGCGGCTTCTGCGCTACCGCCGGGGCCCGGCATAACTC					
55	-MEXICO	CTG C TG C C TCTGG GC C G G CCC C A T					

		2350v	2360v	2370v	2380v	2390v	2400v
	-BURMA	ACCAGACGGCCCCGGCACCGCCGCTGCTCTTACCTACCCGGATGGCTCTAAGGTATTCG					
		C	CG	CGCCGC	T CT	CACCTACCC	GA GGC CTAAG T T G
5	-MEXICO	GCGTTCCGCAG-----CGCCGCTTACTACACACCTACCCTGACGGCGCTAAGATCTATG					
		2410v	2420v	2430v	2440v	2450v	2460v
	-BURMA	CCGGCTCGCTGTTTCGAGTCGACATGCACGTGGCTCGTTAACCGCTCTAATGTTGACCACC					
		CGGCTC	T TTCGAGTC	TGCAC	TGGCT GT AACGC	TCTAA G	G CCACC
10	-MEXICO	TCGGCTCCATTTTCGAGTCTGAGTGCACCTGGCTTGTCACACGATCTAACGCCGGCCACC					
		2470v	2480v	2490v	2500v	2510v	2520v
	-BURMA	GCCCTGGCGGGGGCTTTGCCATGCATTTTACCAAAGGTACCCCGCTCCTTTGATGCTG					
		GCCCTGG	GGCGGGCTTTG	CATGC	TTTT CA	G TACCC G	TC TTTGA GC
15	-MEXICO	GCCCTGGTGGCGGGCTTTGTGCTGCTTTTTTTCAGCGTTACCCGTATTGCTTTGACGCCA					
		2530v	2540v	2550v	2560v	2570v	2580v
	-BURMA	CCTCTTTTGTGATGCGCGACGGCGGGCGCGGTACACACTAACCCCCGGCCAATAATTC					
		CC	TTTGTGATGCG	GA GG	GCCGCGTA	AC CT AC	CCCCGGCC AT ATTC
20	-MEXICO	CCAAGTTTGTGATGCGTGTGCTTTGCCGCGTATACCCTTACACCCGGCCGATCATTC					
		2590v	2600v	2610v	2620v	2630v	2640v
	-BURMA	ACGCTGTCGCCCCCTGATTATAGGTTGGAACATAACCCAAAGAGGCTTGAGGCTGCTTATC					
		A GC GT	GCCCC GA	TAT G	TTGGAACATAACCC	AAGAGGCT	GAGGCTGC TA C
25	-MEXICO	ATGCGGTGGCCCCGGACTATCGATTGGAACATAACCCAAAGAGGCTCGAGGCTGCCTACC					
		2650v	2660v	2670v	2680v	2690v	2700v
	-BURMA	GGGAAACTTGCTCCCGCTCGGCACCGCTGCATACCCGCTCCTCGGGACCGGCATATACC					
		G GA	ACTTGC	CCCGCC	GGCAC	GCTGC TA CC	CTC T GG C GGCAT TACC
30	-MEXICO	GCGAGACTTGCGCCCGCCGAGGCACTGCTGCCTATCCACTCTTAGCGCTGGCATTATCC					
		2710v	2720v	2730v	2740v	2750v	2760v
	-BURMA	AGGTGCCGATCGGCCCCAGTTTTGACGCCTGGGAGCGGAACACCGCCCCGGGATGAGT					
		AGGTGCC	T G	AGTTTTGA	GCCTGGGAGCGGAACACCGCCC	GA GAG	
35	-MEXICO	AGGTGCCTGTTAGTTTGTGATTTTGTGCTGGGAGCGGAACACCGCCCCGTTTGACGAGC					
		2770v	2780v	2790v	2800v	2810v	2820v
	-BURMA	TGTACCTTCTGAGCTTGCTGCCAGATGGTTTGAGGCCAATAGGCCGACCCGCCCCGACTC					
		T TACCT	C GAGCT	GC GC	G TGGTTTGA	CCAA G CC	C CC AC
40	-MEXICO	TTTACCTAACAGAGCTGGCGGCTCGGTGTTTGAATCCAACCGCCCCGGTCAGCCACGT					
		2830v	2840v	2850v	2860v	2870v	2880v
	-BURMA	TCACTATAACTGAGGATGTTGCACGGACAGCGA/ :TGGCCATCGAGCTTGACTCAGCCA					
		T A	ATAACTGAGGAT	GC CG	C GC AA	CTGGCC T	GAGCTTGACTC G A
45	-MEXICO	TGAACATAACTGAGGATACCGCCGCTGCGGCCAACCTGGCCCTGGAGCTTGACTCCGGGA					
		2890v	2900v	2910v	2920v	2930v	2940v
	-BURMA	CAGATGTCGGCCGGGCTGTGCCGGCTGTGCGGTACACCCCGGCGTTGTTTCAGTACCAGT					
		GA GT	GGCCG GC	TGTGCCGG	TGT GTC	CC GGC	TTGT C GTA CAGT
50	-MEXICO	GTGAAGTAGGCCGCGCATGTGCCGGGTGTAAGTCGAGCTGGCGTTGTGCGGTATCAGT					
		2950v	2960v	2970v	2980v	2990v	3000v
	-BURMA	T TACTGCAGGTGTGCTTGATCCGGCAAGTCCCGCTCTATACCCAAGCCGATGTGGACG					
		TTAC GC	GGTGT CC	GG TC	GGCAAGTC	TC T	CA GC GATGTGGA G
55	-MEXICO	TTACAGCCGTTGTCCCCGGCTCTGGCAAGTCAAAGTCCGTGCAACAGGCGGATGTGGATG					

	3010v	3020v	3030v	3040v	3050v	3060v
-BURMA	TTGTCGTGGTCCCCGACGCGTGAGTTGCGTAATGCCTGGCGCCGTCGCGGCTTTGCTGCTT					
	TTGT GT GT CC AC CG GAG T CG AA GC TGGCG CG CG GGCTTTGC GC T					
-MEXICO	TTGTTGTTGTGCCCACTCGCGAGCTTCGGAACGCTTGGCGGCCCGGGGCTTTGCGGCAT					
	3070v	3080v	3090v	3100v	3110v	3120v
-BURMA	TTACCCCGCATACTGCCGCGAGATCACCCAGGGGCGCGGGTTGTTCATTGATGAGGCTC					
	T AC CCGCA ACTGC GCC G GTCAC GG CG GGGTTGTTCATTGATGAGGC C					
-MEXICO	TCACTCCGCACACTGCCGCCGCTGTCACTAGCGGCCGTAGGGTTGTTCATTGATGAGGCC					
	3130v	3140v	3150v	3160v	3170v	3180v
-BURMA	CATCCTCCCCCTCACTGTGTGCTCCACATGCAGCGGGGCCGCCACCGTCCACCTTC					
	C TC CTCCCCC CAC TGCTGCT T CA ATGCAGCG GC GC C GT CACCT C					
-MEXICO	CTTCGCTCCCCCACACTTGTGTCTTTACATATGCAGCGTGTGCATCTGTGCACCTCC					
	3190v	3200v	3210v	3220v	3230v	3240v
-BURMA	TTGGCGACCCGAACAGATCCCAGCCATCGACTTTGAGCACGCTGGGCTCGTCCCCGCCA					
	TTGG GACCCGAA CAGATCCC GCCAT GA TTTGAGCAC C GG CT T CC GC A					
-MEXICO	TTGGGGACCCGAATCAGATCCCCGCCATAGATTTTGAACACACCGGTCTGATTCCAGCAA					
	3250v	3260v	3270v	3280v	3290v	3300v
-BURMA	TCAGGCCCGACTTAGGCCCCACCTCCTGGTGGCATGTTACCCATCGCTGGCCTGCGGATG					
	T GGCC GA TT G CCC AC TC TGGTGGCATGT ACCCA CG TG CCTGC GATG					
-MEXICO	TACGGCCGGAGTTGGTCCCGACTTCATGGTGGCATGTCAACCCACCGTTGCCCTGCAGATG					
	3310v	3320v	3330v	3340v	3350v	3360v
-BURMA	TATGCGAGCTCATCCGTGGTGCATACCCATGATCCAGACCACTAGCCGGGTTCTCCGTT					
	T TG GAG T TCCGTGGTGC TACCC A ATCCAGAC AC AG GGT CTCGTT					
-MEXICO	TCTGTGAGTTAGTCCGTGGTGCTTACCCTAAAATCCAGACTACAAGTAAGGTGCTCCGTT					
	3370v	3380v	3390v	3400v	3410v	3420v
-BURMA	CGTTGTTCTGGGGTGAGCCTGCCGTGGGCGAGAACTAGTGTTCACCCAGGCGGCCAAGC					
	C T TTCTGGGG GAGCC GC GTCGG CAGAA CTAGTGTTCAC CAGGC GC AAG					
-MEXICO	CCCTTTTCTGGGGAGAGCCAGCTGTGCGGCAGAACTAGTGTTCACACAGGCTGCTAAGG					
	3430v	3440v	3450v	3460v	3470v	3480v
-BURMA	CCGCCAACCCCGGCTCAGTGACGGTCCACGAGGCGCAGGGCGCTACCTACACGGAGACCA					
	CCGC ACCCCGG TC T ACGGTCCA GAGGC CAGGG GC AC T AC AC A					
-MEXICO	CCGCGCACCCGGATCTATAACGGTCCATGAGGCCCAGGGTGCCACTTTTACCACTACAA					
	3490v	3500v	3510v	3520v	3530v	3540v
-BURMA	CTATTATTGCCACAGCAGATGCCCGGGGCTTATTACGTGCTCTCGGGCTCATGCCATTG					
	CTAT ATTGC AC GCAGATGCCCG GGCCT AT CAGTC TC CGGGCTCA GC AT G					
-MEXICO	CTATAATTGCAACTGCAGATGCCCGTGGCCTCATACAGTCTCCCGGGCTCACGCTATAG					
	3550v	3560v	3570v	3580v	3590v	3600v
-BURMA	TTGCTCTGACGCGCCACACTGAGAAGTGCGTCATATTGACGCCACAGGCTGCTTCGCG					
	TTGCTCT AC G CA ACTGA AA TG GT AT TTGAC C CC GGCCTG T CG G					
-MEXICO	TTGCTCTCACTAGGCATACTGAAAAATGTGTTATACTTGACTCTCCCGGCTGTTGCGTG					
	3610v	3620v	3630v	3640v	3650v	3660v
-BURMA	AGGTGGGCATCTCCGATGCAATCGTTAATAACTTTTTCTCGCTGGTGGCGAAATTTGGTC					
	AGGTGGG ATCTC GATGC AT GTTAATAA TT TTCT C GGTGGCGA TTGGTC					
-MEXICO	AGGTGGGTATCTCAGATGCCATTGTTAATAATTTCTTCTTTCTGGGTGGCGAGGTTGGTC					

		3670v	3680v	3690v	3700v	3710v	3720v
	-BURMA	ACCAGCGCCCATCAGTTATTTCCCGTGCGCAACCTGACGCCAATGTTGACACCTTGGCTG					
		ACCAG G CCATC GT ATTCC CG GGCAACCTGAC CAATGTTGAC CT GC G					
5	-MEXICO	ACCAGAGACCATCGGTCATTCCGCGAGGCAACCTGACCGCAATGTTGACGTGCTTGC					
		3730v	3740v	3750v	3760v	3770v	3780v
	-BURMA	CCTTCCCGCGCTTTGCCAGATTAGTGCTTCCATCAGTTGGCTGAGGAGCTTGGCCACA					
		C TT CC CC TC TGCCA AT AG GCCTTCCATCAG T GCTGAGGAGCT GGCCAC					
10	-MEXICO	CGTTTCCACCTTCATGCCAATAAGCGCTTCCATCAGCTTGCTGAGGAGCTGGGCCACC					
		3790v	3800v	3810v	3820v	3830v	3840v
	-BURMA	GACCTGTCCCTGTTGCAGCTGTTCTACCACTGCCCCGAGCTCGAACAGGGCCTTCTCT					
		G CC G CC GT GC GCTGT CTACC CCCTGCCC GAGCT GA CAGGGCCTTCTCT					
15	-MEXICO	GGCCGGCGCGGTGGCGGCTGTGCTACCTCCTGCGCTGAGCTTGAGCAGGGCCTTCTCT					
		3850v	3860v	3870v	3880v	3890v	3900v
	-BURMA	ACCTGCCCGAGGAGCTCACCACCTGTGATAGTGTGTAACATTTGAATTAACAGACATTG					
		A CTGCC CAGGAGCT CC CTTGTGA AGTGT GT ACATTTGA TAAC GACATTG					
20	-MEXICO	ATCTGCCACAGGAGCTAGCCTCCTGTGACAGTGTGTGACATTTGAGCTAACTGACATTG					
		3910v	3920v	3930v	3940v	3950v	3960v
	-BURMA	TGCACTGCCGCGATGGCCGCCCCGAGCCAGCGCAAGGCCGTGCTGTCCACACTCGTGGGCC					
		TGCACTGCCGCGATGGC GCCCC AGCCA G AA GC GT TGTCCAC CT GT GGCC					
25	-MEXICO	TGCACTGCCGCGATGGCGGCCCCCTAGCCAAAGGAAAGCTGTTTTGTCCACGCTGGTAGGCC					
		3970v	3980v	3990v	4000v	4010v	4020v
	-BURMA	GCTACGGCGGTGCGACAAAGCTCTACAATGCTTCCCACTCTGATGTTGCGACTCTCTCG					
		G TA GGC G CGCACA GCT TA ATGC CAC C GATGT CGCG CTC CT G					
30	-MEXICO	GGTATGGCAGACGACAAAGGCTTTATGATGCGGGTCACACCGATGTCGCGCCTCCCTTG					
		4030v	4040v	4050v	4060v	4070v	4080v
	-TASHKENT	GGCCCCGTACAGGTACAACTGTGAGTTGTACGAGCTAG					
		GGCCCCGTACAGGT ACAAC TGTGA TTGTACGAGCTAG					
35	-BURMA	CCCGTTTTATCCCGCCATTGGCCCCGTACAGGTTACAACCTGTGAATTGTACGAGCTAG					
		C CG TTTAT CC C T GG C GT G AC AC TGTGAA T T GAGCT G					
	-MEXICO	CGCGCTTTATTTCCCACTCTCGGGCGGGTTACTGCCACCACCTGTGAACCTTTGAGCTTG					
		4090v	4100v	4110v	4120v	4130v	4140v
40	-TASHKENT	TGGAGGCCATGGTCGAGAAAGGCCAGGATGGCTCCGCCGTCTTGAGCTCGATCTCTGCA					
		TGGAGGCCATGGTCGAGAA GGCCAGGATGGCTCCGCCGTCTTGAGCT GATCT TGCA					
	-BURMA	TGGAGGCCATGGTCGAGAAAGGCCAGGATGGCTCCGCCGTCTTGAGCTTGATCTTTGCA					
		T GAGGC ATGGT GAGAAGGGCCA GA GG TC GCCGTCT GAG T GAT T TGCA					
	-MEXICO	TAGAGCGATGGTGGAGAAGGGCCAAGACGGTTCAGCCGTCTCGAGTTGGATTGTGCA					
45		4150v	4160v	4170v	4180v	4190v	4200v
	-TASHKENT	ACCGTGACGTGTCCAGGATCACCTTTTTCCAGAAAGATTGCAATAAGTTACACAGGGAG					
		ACCGTGACGTGTCCAGGATCACCTT TTCCAGAAAGATTG AA AAGTTACACAC GG G					
	-BURMA	ACCGTGACGTGTCCAGGATCACCTTCTTCCAGAAAGATTGTAACAAGTTACACAGGGT					
		CCG GA GT TCC G AT ACCTT TTCCAGAA GATTGTAACAAGTTACAC AC GG G					
50	-MEXICO	GCCGAGATGTCTCCGCATAACCTTTTTCCAGAAAGATTGTAACAAGTTACACAGGGCG					

0955 1410.021502

		4210v	4220v	4230v	4240v	4250v	4260v
	-TASHKENT	AGACCATCGCCCATGGTAAAGTGGGCCAGGGCATTTCGGCCTGGAGTAAGACCTTCTGTG					
		AGACCAT GCCCATGGTAAAGTGGGCCAGGGCATTTCGGCCTGGAG	AAGACCTTCTG G				
5	-BURMA	AGACCATGCCCCATGGTAAAGTGGGCCAGGGCATCTCGGCCTGGAGCAAGACCTTCTGCG					
		AGAC ATTGC CATGG AAAGT GG CAGGG ATCT	CTGGAG AAGAC TT TG G				
	-MEXICO	AGACAATTGCGCATGGCAAAGTCGGTCAGGGTATCTTCGCTGGAGTAAGACGTTTTGTG					
		4270v	4280v	4290v	4300v	4310v	4320v
10	-TASHKENT	CCCTTTTCGGCCCTGGTTCGGTGCTATTGAGAAGGCTATTCTGGCCCTGCTCCCTCAGG					
		CCCT TT GGCC TGGTTCG GCTATTGAGAAGGCTATTCTGGCCCTGCTCCCTCAGG					
	-BURMA	CCCTCTTTGGCCCTTGGTTCGGCGCTATTGAGAAGGCTATTCTGGCCCTGCTCCCTCAGG					
		CCCT TTTGGCC TGGTTCG GC ATTGAGAAGGCTATTCT	CCCT T CC CA G				
	-MEXICO	CCCTGTTTGGCCCTGGTTCGGTGCGATTGAGAAGGCTATTCTATCCCTTTTACCACAAG					
		4330v	4340v	4350v	4360v	4370v	4380v
15	-TASHKENT	GTGTGTTTTATGGGGATGCCTTTGATGACACCGTCTTCTCGGCGGTGTGGCCGACGAA					
		GTGTGTTTTA GG GATGCCTTTGATGACACCGTCTTCTCGGCG	TGTGGCCGACGAA				
	-BURMA	GTGTGTTTTACGGTGATGCCTTTGATGACACCGTCTTCTCGGCGGTGTGGCCGACGAA					
		TGTGT TACGG GATGC T TGA GAC C GT TTCT GC GC GTGGC G GC A					
20	-MEXICO	CTGTGTTCTACGGGGATGCTTATGACGACTCAGTATTCTCTGCTGCCGTGGCTGGCGCCA					
		4390v	4400v	4410v	4420v	4430v	4440v
	-TASHKENT	AGGCGTCCATGGTGTGGAATGACTTTTCTGAGTTTGACTCCACCCAGAATAATTTTT					
		AGGC TCCATGGTGTGGAATGACTTTTCTGAGTTTGACTCCACCCAGAATAA TTTT					
25	-BURMA	AGGCATCCATGGTGTGGAATGACTTTTCTGAGTTTGACTCCACCCAGAATAACTTTT					
		CCATGGTGTGGA AATGA TTTTCTGAGTTTGACT AC CAGAATAACTTTT					
	-MEXICO	GCCATGCCATGGTGTGAAAATGATTTTCTGAGTTTGACTCGACTCAGAATAACTTTT					
		4450v	4460v	4470v	4480v	4490v	4500v
30	-TASHKENT	CCCTGGGCTAGAGTGTGCTATTATGGAGAAGTGTGGGATGCCGAAGTGGCTCATCCGCT					
		C CTGGG CTAGAGTGTGCTATTATGGAG AGTGTGGGATGCC AGTGGCTCATCCG					
	-BURMA	CTCTGGGCTAGAGTGTGCTATTATGGAGGAGTGTGGGATGCCGAGTGGCTCATCCGCC					
		C CT GGTCT GAGTG GC ATTATGGA GAGTGTGG ATGCC CAGTGGCT TC G					
35	-MEXICO	CCCTAGGTCTTGAGTGCGCCATTATGGAAGAGTGTGGTATGCCCCAGTGGCTTGTCAAGT					
		4510v	4520v	4530v	4540v	4550v	4560v
	-TASHKENT	TGTACCACCTTATAAGGTCTGCGTGGATCCTGCAGGCCCCGAAGGAGTCCCTGCGAGGGT					
		TGTA CACCTTATAAGGTCTGCGTGGATC TGCAGGCCCCGAAGGAGTCTGCGAGGGT					
40	-BURMA	TGTATCACCTTATAAGGTCTGCGTGGATCCTGCAGGCCCCGAAGGAGTCTCTGCGAGGGT					
		TGTA CA T GGTC GCGTGGATC TGCAGGCCCC AA GAGTCT TG GAGGGT					
	-MEXICO	TGTACCATGCCGTCCGGTCGCGTGGATCCTGCAGGCCCCAAAGAGTCTTTGAGAGGGT					
		4570v	4580v	4590v	4600v	4610v	4620v
45	-TASHKENT	GTTGGAAGAAACACTCCGGTGAGCCCGGCACTCTTCTATGGAATACTGTCTGGAACATGG					
		TTGGAAGAAACACTCCGGTGAGCCCGGCACTCTTCTATGGAATACTGTCTGGAA ATGG					
	-BURMA	TTTGAAGAAACACTCCGGTGAGCCCGGCACTCTTCTATGGAATACTGTCTGGAATATGG					
		T TGAAGAA CA TC GGTGAGCC GGCA T CT TGAATAC GT TGGAA ATGG					
	-MEXICO	TCTGGAAGAAGCATTCTGGTGAGCCGGGAGCTTGCTCTGGAATACGGTGTGGAACATGG					
		4630v	4640v	4650v	4660v	4670v	4680v
50	-TASHKENT	CCGTTATACCCATTGTTACGATTTCCGCGATTTGCAGGTGGCTGCCTTTAAAGGTGATG					
		CCGTTAT ACCCA TGTTA GA TTCCGCGATTT AGGTGGCTGCCTTTAAAGGTGATG					
	-BURMA	CCGTTATTACCCACTGTTATGACTTCCGCGATTTTCAGGTGGCTGCCTTTAAAGGTGATG					
		C T ATT CCA TG TATGA TTCCG GA T CAGGT GC GCCTT AA GG GA G					
55	-MEXICO	CAATCATGCCCCATTGCTATGAGTTCCGGGACCTCCAGGTTCGCGCTTCAAGGGGACG					

0051410.021902

		4690v	4700v	4710v	4720v	4730v	4740v
5	-TASHKENT	ATTCGATAGTGCTTTGCAGTGAGTACCGTCAGAGTCCAGGGGCTGCTGTCCTGATTGCTG ATTCGATAGTGCTTTGCAGTGAGTA CGTCAGAGTCCAGG GCTGCTGTCCTGAT GC G					
	-BURMA	ATTCGATAGTGCTTTGCAGTGAGTATCGTCAGAGTCCAGGAGCTGCTGTCCTGATCGCCG A TCG T GT CT TG AGTA TA CG CAGAG CCAGG GC G T CT AT GC G					
	-MEXICO	ACTCGGTCGTCTCTGTAGTGAATACCGCCAGAGCCAGGCGCCGGTTCGCTTATAGCAG					
10		4750v	4760v	4770v	4780v	4790v	4800v
	-TASHKENT	GCTGTGGCTTAAAGCTGAAGGTGGGTTTCCGTCGATTGGTTTGTATGCAGGTGTTGTGG GCTGTGGCTT AAG TGAAGST G TTTCCG CCGAT GGTTTGTATGCAGGTGTTGTGG					
	-BURMA	GCTGTGGCTTGAAGTTGAAGGTAGATTTCCGCCGATCGGTTTGTATGCAGGTGTTGTGG GCTGTGG TTGAAGTTGAAGG GA TTTCCG CCGAT GG TGTATGC GG GTTGT G					
	-MEXICO	GCTGTGGTTTGAAGTTGAAGGCTGACTTCCGCCGATTGGGCTGTATGCCGGGGTTGTGC					
15		4810v	4820v	4830v	4840v	4850v	4860v
	-TASHKENT	TGACCCCGGCCCTTGGCGCGCTTCCCGACGTCGTGCGCTTGTCCGGCCGGCTTACTGAGA TG CCCCCGGCCTTGGCGCGCTTCCCGA GT GTGCGCTTG CCGGCCGGCTTAC GAGA					
	-BURMA	TGGCCCCCGGCCCTTGGCGCGCTCCCTGATGTTGTGCGCTTCGCCGCCGGCTTACCGAGA T GCCCC GG CT GG GC CT CC GATGT GT CG TTCGCCG CGGCTT C GAGA					
	-MEXICO	TCGCCCCGGGGCTCGGGGCCCTACCCGATGTCGTTTCGATTCCGCCGACGGCTTTCGGAGA					
20		4870v	4880v	4890v	4900v	4910v	4920v
	-TASHKENT	AGAATTGGGGCCCTGGCCCTGAGCGGGCGGAGCAGCTCCGCCTTGCTGT AGAATTGGGGCCCTGGCCCTGAGCGGGCGGAGCAGCTCCGCCT GCTGT					
	-BURMA	AGAATTGGGGCCCTGGCCCTGAGCGGGCGGAGCAGCTCCGCCTCGCTGTTAGTGATTTC AGAA TGGGG CCTG CC GAGCGGC GAGCAGCTCCGCCTCGC GT GATTTC					
	-MEXICO	AGAACTGGGGCCCTGATCCGAGCGGGCAGAGCAGCTCCGCCTCGCGTGCAGGATTTC					
25		4930v	4940v	4950v	4960v	4970v	4980v
	-BURMA	TCCGCAAGCTCACGAATGTAGCTCAGATGTGTGTGGATGTTGTTTCCCGTGTATGGGG TCCG A G T ACGAATGT GC CAGAT TGTGT GA GT TC G GTTTA GGGG					
	-MEXICO	TCCGTAGGTTAACGAATGTGGCCAGATTGTTGTTGAGGTGGTGTCTAGAGTTACGGGG					
30		4990v	5000v	5010v	5020v	5030v	5040v
	-BURMA	TTTCCCCTGGACTCGTTCATAACCTGATTGGCATGCTACAGGCTGTTGCTGATGGCAAGG TTTCCCC GG CT GTTCATAACCTGAT GGCATGCT CAG CT TTG TGATGG AAGG					
	-MEXICO	TTTCCCCGGGTCTGGTTCATAACCTGATAGGCATGCTCCAGACTATTGGTGATGGTAAGG					
35		5050v	5060v	5070v	5080v	5090v	5100v
	-BURMA	CACATTTCACTGAGTCAGTAAAACAGTGCTCGACTTGACAAATTCAATCTTGTGTGGG C CATTT AC GAGTC GT AA CC T CT GAC T ACA A TCAAT TG CGG					
	-MEXICO	CGCATTTTACAGAGTCTGTTAAGCCTATACTTGACCTTACACACTCAATTATGCACCGGT					
40		5110v	5120v	5130v	5140v	5150v	5160v
	-BURMA	TGGAATGAATAACATGTCTTTTGTGCGCCCATGGGTTGCGACCATGCGCCCTCGGCCT GAATGAATAACATGT TTTGCTGCGCCCATGGGTTGCG ACCATGCGCCCT GGCCT					
	-MEXICO	CTGAATGAATAACATGTGGTTTGTGCGCCCATGGGTTGCGCCCATGCGCCCTAGGCCT					
45		5170v	5180v	5190v	5200v	5210v	5220v
	-BURMA	ATTTTGTGCTGCTCCTCATGTTTTTGCCTATGCTGCCCGGCCACCGCCCGGTGAGCCG TTTTG TG TG TCCTC TGTTC TGCCTATG TGCCTGCGCCACCG CCGGTGAGCCG					
	-MEXICO	CTTTTGTGTTGTTCTCTCTGTTTCTGCCTATGTTGCCCGGCCACCGACCGGTGAGCCG					

		5230v	5240v	5250v	5260v	5270v	5280v
	-BURMA	TCTGGCCGCGCTCGTGGGCGGCGCAGCGGCGTTCGGCGGTGGTTTCTGGGGTGACCGG					
		TCTGGCCGCGCTCGTGGGCGGCGCAGCGGCGT CCGCGGTGGTTTCTGGGGTGACCGG					
	-MEXICO	TCTGGCCGCGCTCGTGGGCGGCGCAGCGGCGTACCGCGGTGGTTTCTGGGGTGACCGG					
5		5290v	5300v	5310v	5320v	5330v	5340v
	-BURMA	GTTGATTCTCAGCCCTTCGCAATCCCTATATTCATCCAACCAACCCCTTCGCCCCGAT					
		GTTGATTCTCAGCCCTTCGCAATCCCTATATTCATCCAACCAACCCCTT GCCC GA					
	-MEXICO	GTTGATTCTCAGCCCTTCGCAATCCCTATATTCATCCAACCAACCCCTTTGCCCCAGAC					
10		5350v	5360v	5370v	5380v	5390v	5400v
	-BURMA	GTCACCGCTGCGGGCGGGGCTGGACCTCGTGTCGCCAACCCGCCGACCACTCGGCTCC					
		GT CCGCTGCG CCGGG CTGGACCTCG TTGCCAACCC GCCG CCACT GGCTCC					
	-MEXICO	GTTGCCGCTGCGCTCCGGGCTGGACCTCGCTTCGCCAACCAAGCCCGGCCACTTGGCTCC					
15		5410v	5420v	5430v	5440v	5450v	5460v
	-BURMA	GCTTGGCGTGACCAAGGCCAGCGCCCGCGCTTGCTCAGCTCGTAGACCTACCACAGCT					
		CTTGGCG GA CAGGCCAGCGCCCC CCG TGCTC CGTCG GACCT CCACAGC					
	-MEXICO	ACTTGGCGAGATCAGGCCAGCGCCCTCCGCTGCTCCCGTCGCCGACCTGCCACAGCC					
20		5470v	5480v	5490v	5500v	5510v	5520v
	-BURMA	GGGGCCGCGCCGCTAACCGCGGTGCTCCGGCCCATGACACCCCGCCAGTGCTGATGTC					
		GGGGC GCG CGCT AC GC GT GC CC GCCCATGACACC C CC GT CC GA GT					
	-MEXICO	GGGGCTGCGGCGCTGACGGCTGTGGCGCTGCCCATGACACCTACCCGTCGCCGACGTT					
25		5530v	5540v	5550v	5560v	5570v	5580v
	-BURMA	GACTCCCGCGCGCCATCTTGCGCCGCGAGTATAACCTATCAACATCTCCCTTACCTCT					
		GA TC CGCGG GC AT T CGCCG CAGTATAA T TC AC TC CCCT AC TC					
	-MEXICO	GATTCTCGCGGTGCAATTCTACGCCGCGAGTATAATTTGTCTACTTCACCCCTGACATCC					
30		5590v	5600v	5610v	5620v	5630v	5640v
	-BURMA	TCCGTGGCCACCGGCACTAACCTGGTTCTTTATGCGCCCTCTTAGTCCGCTTTTACCC					
		TC GTGGCC C GGCATAA T GT CT TATGC GCCC CTTA TCCG T T CC					
	-MEXICO	TCTGTGGCTCTGGCACTAATTTAGTCTGTATGACGCCCCCTTAATCCGCCTCTGCCG					
35		5650v	5660v	5670v	5680v	5690v	5700v
	-BURMA	CTTCAGGACGGCACCATAACCATATAATGGCCACGGAAGCTTCTAATTATGCCAGTAC					
		CT CAGGACGG AC AATAC CA AT ATGGCCAC GA GC TC AATTATGC CAGTAC					
	-MEXICO	CTGCAGGACGGTACTAATACTCACATTATGGCCACAGAGGCTCCAATTATGCACAGTAC					
40		5710v	5720v	5730v	5740v	5750v	5760v
	-BURMA	CGGGTTGCCCGTGCCACAATCCGTTACCGCCCGTGTTGCCCAATGCTGTGCGGCTTAC					
		CGGGTTGCCG GC AC ATCCGTTACCG CC CT GT CC AATGC GT GG GG TA					
	-MEXICO	CGGGTTGCCCGCTACTATCCGTTACCGCCCCCTAGTGCTAATGCAGTTGGAGGCTAT					
45		5770v	5780v	5790v	5800v	5810v	5820v
	-BURMA	GCCATCTCCATCTCATTCTGGCCACAGACCACCACCACCCGACGTCCGTTGATATGAAT					
		GC AT TCCAT TC TTCTGGCC CA AC ACCAC ACCCC AC TC GTTGA ATGAAT					
	-MEXICO	GCTATATCCATTTCTTCTGGCCCTCAAACAACCAACCCCTACATCTGTTGACATGAAT					
50		5830v	5840v	5850v	5860v	5870v	5880v
	-BURMA	GCTATATCCATTTCTTCTGGCCCTCAAACAACCAACCCCTACATCTGTTGACATGAAT					
		GCTATATCCATTTCTTCTGGCCCTCAAACAACCAACCCCTACATCTGTTGACATGAAT					
	-MEXICO	GCTATATCCATTTCTTCTGGCCCTCAAACAACCAACCCCTACATCTGTTGACATGAAT					

5830v 5840v 5850v 5860v 5870v 5880v
 -BURMA TCAATAACCTCGACGGATGTTCTGATTTTTAGTCCAGCCCGCATAGCCTCTGAGCTTGTG
 TC AT AC TC AC GATGT G ATT T GT CA CC GGCATAGC TCTGA T GT
 -MEXICO TCCATTACTTCCACTGATGTGTCAGGATTCTTGTTCACCTGGCATAGCATCTGAATTGGTCT

5890v 5900v 5910v 5920v 5930v 5940v
 -BURMA ATCCCAAGTGAGCGCCTACACTATCGTAACCAAGGCTGGCGCTCCGTCGAGACCTCTGGG
 ATCCCAAG GAGCGCCT CACTA CG AA CAAGG TGGCGCTC GT GAGAC TCTGG
 -MEXICO ATCCCAAGCGAGCGCCTTCACTACCGCAATCAAGGTTGGCGCTCGGTTGAGACATCTGGT

5950v 5960v 5970v 5980v 5990v 6000v
 -BURMA GTGGCTGAGGAGGAGGCTACCTCTGGTCTTGTATGCTTTGCATACATGGCTCACTCGTA
 GT GCTGAGGAGGA GC ACCTC GGTCTGT ATG T TGCATACATGGCTC C GT
 -MEXICO GTTGCTGAGGAGGAAGCCACCTCCGGTCTTGTGTCATGTTATGCATACATGGCTCTCCAGTT

6010v 6020v 6030v 6040v 6050v 6060v
 -BURMA AATTCTATACTAATACACCCTATACCGGTGCCCTCGGGCTGTTGGACTTTGCCCTTGAG
 AA TCCTATAC AATAC CC TATACCGGTGCCCT GG T TGGACTTTGCC T GAG
 -MEXICO AACTCTATACCAATACCCCTTATACCGGTGCCCTTGGCTTACTGGACTTTGCCCTTAGAG

6070v 6080v 6090v 6100v 6110v 6120v
 -BURMA CTTGAGTTTCGCAACCTTACCCCGGTAACACCAATACGCGGGCTCCTCCGTTATTCCAGC
 CTTGAGTTTCGCAA CT ACC CC GTAACACCAATAC CG GT TCCCGTTA TCCAGC
 -MEXICO CTTGAGTTTCGCAATCTCACCCCTGTAACACCAATACACGTGTGTGCCGTTACTCCAGC

6130v 6140v 6150v 6160v 6170v 6180v
 -BURMA ACTGCTCGCCACCGCTTCGTGCGGTGCGGACGGGACTGCGGAGCTCACCACCACGGCT
 ACTGCTCG CAC C CG G G GACGGGACTGC GAGCT ACCAC AC GC
 -MEXICO ACTGCTCGTCACTCCGCCGAGGGGCC---GACGGGACTGCGGAGCTGACCACAATGCA

6190v 6200v 6210v 6220v 6230v 6240v
 -BURMA GCTACCCGCTTTATGAAGGACCTCTATTTTACTAGTACTAATGGTGTGCGTGAGATCGGC
 GC ACC G TT ATGAA GA CTC A TTTAC G TAATGG GT GGTGA TCGGC
 -MEXICO GCCACCAGGTTTCATGAAAGATCTCCACTTTACCGGCCTTAATGGGGTAGGTGAAGTCCGC

6250v 6260v 6270v 6280v 6290v 6300v
 -BURMA CGCGGGATAGCCCTCACCTGTTCACCTTGCTGACACTCTGCTTGGCGGCTTCCGACA
 CGCGGGATAGC CT AC T T AACCTTGCTGACAC CT CT GCGCG CT CCGACA
 -MEXICO CGCGGGATAGCTCTAACATTACTTAACCTTGCTGACACGCTCCTCGCGGGCTCCGACA

6310v 6320v 6330v 6340v 6350v 6360v
 -BURMA GAATTGATTTCTGTCGGCTGGTGGCCAGCTGTTCTACTCCCGTCCCGTTGTCTCAGCCAAT
 GAATT ATTTCTGTCGGCTGG GG CA CTGTT TA TCCG CC GTTGTCTCAGCCAAT
 -MEXICO GAATTAATTTCTGTCGGCTGGCGGGCAACTGTTTTATTCCCGCCCGGTTGTCTCAGCCAAT

6370v 6380v 6390v 6400v 6410v 6420v
 -BURMA GGCGAGCCGACTGTTAAGTTGTATACATCTGTAGAGAATGCTCAGCAGGATAAGGGTATT
 GGCGAGCC AC GT AAG T TATACATC GT GAGAATGCTCAGCAGGATAAGGGT TT
 -MEXICO GGCGAGCCAACCGTGAAGCTCTATACATCAGTGGAGAATGCTCAGCAGGATAAGGGTGT

6430v 6440v 6450v 6460v 6470v 6480v
 -BURMA GCAATCCCGCATGACATTGACCTCGGAGAATCTCGTGTGGTTATTCAGGATTATGATAAC
 GC ATCCC CA GA AT GA CT GG GA TC CGTGTGGT ATTACGATTATGA GA
 -MEXICO GCTATCCCCCAGGATATCGATCTTGGTGATTGCGGTGTGGTCAATCAGGATTATGACAA

	6490v	6500v	6510v	6520v	6530v	6540v
-BURMA	CAACATGAACAAGATCGGCCGACGCTTCTCCAGCCCCATCGCGCCCTTTCTCTGTCCTT					
-MEXICO	CA CATGA CA GATCGGCC AC CC TC CC GC CCATC CG CCTTT TCTGT CT					
	6550v	6560v	6570v	6580v	6590v	6600v
-BURMA	CGAGCTAATGATGTGCTTTGGCTCTCTCACCCTGCGCAGTATGACCAGTCCACTTAT					
-MEXICO	CGAGC AATGATGT CTTTGGCT TC CTCAC GC GCCGAGTATGACCAGTCCACTTA					
	6610v	6620v	6630v	6640v	6650v	6660v
-BURMA	GGCTCTTCGACTGGCCAGTTTATGTTTCTGACTCTGTGACCTTGGTTAATGTTGCGACC					
-MEXICO	GG TC TC ACTGGCCC GTTTAT T TC GAC GTGAC TTGGT AATGTTGCGAC					
	6670v	6680v	6690v	6700v	6710v	6720v
-BURMA	GGCGCGCAGGCCGTTGCCCGGTGCTCGATTGGACCAAGGTCACACTTGACGGTCGCCCC					
-MEXICO	GGCGCGCAGGCCGT GCCG TCGCT GA TGG CCAA GTCAC CT GACGG CG CCC					
	6730v	6740v	6750v	6760v	6770v	6780v
-BURMA	CTCTCCACCATCCAGCAGTACTCGAAGACCTTCTTTGTCTCGCCGCTCCGCGTAAGCTC					
-MEXICO	CTC C AC T AGCA TA TC AAGAC TTCTTTGT CT CC CT CG GG AAGCTC					
	6790v	6800v	6810v	6820v	6830v	6840v
-BURMA	TCTTTCTGGGAGGCAGGCACAACATAAGCCGGGTACCTTTATAATTATAACCACTGCT					
-MEXICO	TC TT TGGGAGGC GGCACAAC AAAGC GG TA CTTTATAATTATAA AC ACTGCT					
	6850v	6860v	6870v	6880v	6890v	6900v
-BURMA	AGCGACCAACTGCTTTGTCGAGAATGCCGCCGGGCACCGGGTCTGCTATTTCCACTTACACC					
-MEXICO	AG GACCA T CT T GA AATGC GCCGG CA CGGGTCGC ATTTT AC TA ACC					
	6910v	6920v	6930v	6940v	6950v	6960v
-BURMA	ACTAGCCTGGGTGCTGGTCCCGTCTCCATTTCTGCGGTTGCCGTTTTAGCCCCCACTCT					
-MEXICO	AC AG CT GG GC GGTCC GTC CCATTTCTGCGG GC GTTTT GC CC C CTC					
	6970v	6980v	6990v	7000v	7010v	7020v
-BURMA	GCGCTAGCATTGCTTGAGGATACCTTGACTACCCTGCCCGCGCCCACTTTTGATGAT					
-MEXICO	GC CT GC TGCT GAGGATAC TT GA TA CC G CG GC CA AC TTTGATGA					
	7030v	7040v	7050v	7060v	7070v	7080v
-BURMA	TTCTGCCCAGAGTGCCGCCCTTGGCCTTCAGGGCTGCGCTTTCAGTCTACTGTGCGCT					
-MEXICO	TTCTGCCC GA TGCCGC C T GGCCT CAGGG TG GCTTTCAGTC ACTGTGCGCT					
	7090v	7100v	7110v	7120v	7130v	7140v
-BURMA	GAGCTTCAGCGCCTTAAGATGAAGGTGGGTAAAACTCGGGAGTTGTAGTTTATTGCTTG					
-MEXICO	GAGCT CAGCGCCTTAA T AAGGTGGGTAAAACTCGGGAGTTGTAGTTTATTG TG					

5

	7150v	7160v	7170v	7180v	7190v
-BURMA	TGCCCCCCTTCTTTCTGTTGC-----TTATTTCTCATTTCTGCGTTCCGCGCTCCC				
	TGCCC CCT CTT TGC	TTATTTT	TTTCT	GT	CCGCGCTCCC
-MEXICO	TGCCCACCTACTTATATCTGCTGATTTTCCTTTATTTCTTTTTCTCGGTCCCGCGCTCCC				

10

	v 7195
-BURMA	TGA
	TGA
-MEXICO	TGA

15 A number of open reading frames, which are potential coding regions, have been found within the DNA sequences set forth above. As has already been noted, consensus residues for the RNA-directed RNA polymerase (RDRP) were identified in the HEV (Burma) strain clone ET1.1. Once a contiguous overlapping set of clones was accumulated, it became clear that the nonstructural elements containing the RDRP as well as

20 what were identified as consensus residues for the helicase domain were located in the first large open reading frame (ORF1). ORF1 covers the 5' half of the genome and begins at the first encoded met, after the 27th bp of the apparent non-coding sequence, and then

25 extends 5079 bp before reaching a termination codon. Beginning 37 bp downstream from the ORF1 stop codon in the plus 1 frame is the second major opening reading frame (ORF2) extending 1980 bp and terminating 68 bp upstream from the point of poly A addition. The third

30 forward ORF (in the plus 2 frame) is also utilized by HEV. ORF3 is only 370 bp in length and would not have been predicted to be utilized by the virus were it not for the identification of the immunoreactive cDNA clone 406.4-2 from the Mexico SISPA cDNA library (see

35 below for detailed discussion). This epitope confirmed the utilization of ORF3 by the virus, although the means by which this ORF is expressed has not yet been fully elucidated. If we assume that the first ~~met~~ is utilized, ORF3 overlaps ORF1 by 1 bp at

40 its 5' end and ORF2 by 328 bp at its 3' end. ORF2 contains the broadly reactive 406.3-2 epitope and also

U551410-021502

a signal sequence at its extreme 5' end. The first half of this ORF2 also has a high pI value (>10) similar to that seen with other virus capsid proteins. These data suggest that the ORF2 might be the predominant structural gene of HEV.

5 The existence of subgenomic transcripts prompted a set of experiments to determine whether these RNAs were produced by splicing from the 5' end of the genome. An analysis using subgenomic probes from throughout the genome, including the extreme 5' end, did not provide evidence for a spliced transcript. However, it was discovered that a region of the genome displayed a high degree of homology with a 21 bp segment identified in Sindbis as a probably internal initiation site for RNA transcription used in the production of its subgenomic messages. Sixteen of 21 (76%) of the nucleotides are identical.

Two cDNA clones which encode an epitope of HEV that is recognized by sera collected from different ET-NANB outbreaks (i.e., a universally recognized epitope) have been isolated and characterized. One of the clones immunoreacted with 8 human sera from different infected individuals and the other clone immunoreacted with 7 of the human sera tested. Both clones immunoreacted specifically with cyno sera from infected animals and exhibited no immunologic response to sera from uninfected animals. The sequences of the cDNAs in these recombinant phages, designated 406.3-2 and 406.4-2 have been determined. The HEV open reading frames are shown to encode epitopes specifically recognized by sera from patients with HEV infections. The cDNA sequences and the polypeptides that they encode are set forth below.

Epitopes derived from Mexican strain of HEV:

35 406.4-2 sequence (nucleotide sequence has SEQ ID NO.13; amino acid sequence has SEQ ID NO.14):

SEQ ID NO. 13:

5	C GCC AAC CAG CCC GGC CAC TTG GCT CCA CTT GGC GAG ATC AGG CCC Ala Asn Gln Pro Gly His Leu Ala Pro Leu Gly Glu Ile Arg Pro	46
	1 5 10 15	
10	AGC GCC CCT CCG CTG CCT CCC GTC GCC GAC CTG CCA CAG CCG GGG CTG Ser Ala Pro Pro Leu Pro Pro Val Ala Asp Leu Pro Gln Pro Gly Leu	94
	20 25 30	
15	CGG CGC TGA CGGCTGTGGC GCCTGCCCAT GACACCTCAC CCGTCCCGGA Arg Arg	143
20	CGTTGATTCT CGCGGTGCAA TTCTACGCCG CCAGTATAAT TTGTCTACTT CACCCCTGAC ATCCTCTGTG GCCTCTGGCA CTAATTTAGT CCTGTATGCA GCCCCCCTTA ATCCGCCTCT GCCGCTGCAG GACGGTACTA ATACTCACAT TATGGCCACA GAGGCCTCCA ATTATGCACA GTACCGGGTT GCCCGCGCTA CTATCCGTTA CCGGCCCTTA GTGCCTAATG CAGTTGGAGG CTATGCTATA TCCATTTCTT TCTGGCCTCA AACAACCACA ACCCCTACAT CTGTTGACAT GAATTC	203 263 323 383 443 449

SEQ ID NO. 14:

30	Ala Asn Gln Pro Gly His Leu Ala Pro Leu Gly Glu Ile Arg Pro Ser 1 5 10 15 Ala Pro Pro Leu Pro Pro Val Ala Asp Leu Pro Gln Pro Gly Leu Arg 20 25 30 Arg
----	--

406.3-2 sequence (nucleotide sequence has SEQ ID NO.15; amino acid sequence has SEQ ID NO.16):

SEQ ID NO. 15:

40	GGAT ACT TTT GAT TAT CCG GGG CGG GCG CAC ACA TTT GAT GAC TTC TGC Thr Phe Asp Tyr Pro Gly Arg Ala His Thr Phe Asp Asp Phe Cys 1 5 10 15	49
45	CCT GAA TGC CGC GCT TTA GGC CTC CAG GGT TGT GCT TTC CAG TCA ACT Pro Glu Cys Arg Ala Leu Gly Leu Gln Gly Cys Ala Phe Gln Ser Thr 20 25 30	97
50	GTC GCT GAG CTC CAG CGC CTT AAA GTT AAG GTT Val Ala Glu Leu Gln Arg Leu Lys Val Lys Val 35 40	130

[illegible]

5

10

15

20

25

30

35

35

40

other sources of genetic material), as is well known in the art.

3. Two amino acid sequences or two nucleotide sequences (in an alternative definition for homology between two nucleotide sequences) are considered homologous (as this term is preferably used in this specification) if they have an alignment score of >5 (in standard deviation units) using the program ALIGN with the mutation gap matrix and a gap penalty of 6 or greater. See Dayhoff, M.O., in Atlas of Protein Sequence and Structure (1972) Vol. 5, National Biomedical Research Foundation, pp. 101-110, and Supplement 2 to this volume, pp. 1-10. The two sequences (or parts thereof, preferably at least 30 amino acids in length) are more preferably homologous if their amino acids are greater than or equal to 50% identical when optimally aligned using the ALIGN program mentioned above.

4. A DNA fragment is "derived from" an ET-NANB
20 viral agent if it has the same or substantially the
same basepair sequence as a region of the viral agent
genome.

5. A protein is "derived from" an ET-NANB viral agent if it is encoded by an open reading frame of a DNA or RNA fragment derived from an ET-NANB viral agent.

II. Obtaining Cloned ET-NANB Fragments

According to one aspect of the invention, it has been found that a virus-specific DNA clone can be produced by (a) isolating RNA from the bile of a cynomolgus monkey having a known ET-NANB infection, (b) cloning the cDNA fragments to form a fragment library, and (c) screening the library by differential hybridization to radiolabeled cDNAs from infected and non-infected bile sources.

A. cDNA Fragment Mixture

ET-NANB infection in cynomolgus monkeys is initiated by inoculating the animals intravenously with a 10% w/v suspension from human case stools positive for 27-34 nm ET-NANB particles (mean diameter 32 nm). An infected animal is monitored for elevated levels of alanine aminotransferase, indicating hepatitis infection. ET-NANB infection is confirmed by immunospecific binding of seropositive antibodies to virus-like particles (VLPs), according to published methods (Gravelle). Briefly, a stool (or bile) specimen taken from the infected animal 3-4 weeks after infection is diluted 1:10 with phosphate-buffered saline, and the 10x suspension is clarified by low-speed centrifugation and filtration successively through 1.2 and 0.45 micron filters. The material may be further purified by pelleting through a 30% sucrose cushion (Bradley). The resulting preparation of VLPs is mixed with diluted serum from human patients with known ET-NANB infection. After incubation overnight, the mixture is centrifuged overnight to pellet immune aggregates, and these are stained and examined by electron microscopy for antibody binding to the VLPs.

ET-NANB infection can also be confirmed by seroconversion to VLP-positive serum. Here the serum of the infected animal is mixed as above with 27-34 nm VLPs isolated from the stool specimens of infected human cases and examined by immune electron microscopy for antibody binding to the VLPs.

Bile can be collected from ET-NANB positive animals by either cannulating the bile duct and collecting the bile fluid or by draining the bile duct during necropsy. Total RNA is extracted from the bile by hot phenol extraction, as outlined in Example 1A. The RNA fragments are used to synthesize corresponding duplex cDNA fragments by random priming, also as referenced in Example 1A. The cDNA fragments may be fractionated by gel electrophoresis or density

gradient centrifugation to obtain a desired size class of fragments, e.g., 500-4,000 basepair fragments.

Although alternative sources of viral material, such as VLPs obtained from stool samples (as described in Example 4), may be used for producing a CDNA fraction, the bile source is preferred. According to one aspect of the invention, it has been found that bile from ET-NANB-infected monkeys shows a greater number of intact viral particles than material obtained from stool samples, as evidenced by immune electron microscopy. Bile obtained from an ET-NANB infected human or cynomolgus macaque, for use as a source of ET-NANB viral protein or genomic material, or intact virus, forms part of the present invention.

15

B. cDNA Library and Screening

The cDNA fragments from above are cloned into a suitable cloning vector to form a cDNA library. This may be done by equipping blunt-ended fragments with a suitable end linker, such as an EcoRI sequence, and inserting the fragments into a suitable insertion site of a cloning vector, such as at a unique EcoRI site. After initial cloning, the library may be re-cloned, if desired, to increase the percentage of vectors containing a fragment insert. The library construction described in Example 1B is illustrative. Here cDNA fragments were blunt-ended, equipped with EcoRI ends, and inserted into the EcoRI site of the lambda phage vector gt10. The library phage, which showed less than 5% fragment inserts, was isolated, and the fragment inserts re-cloned into the lambda gt10 vector, yielding more than 95% insert-containing phage.

The cDNA library is screened for sequences specific for ET-NANB by differential hybridization to cDNA probes derived from infected and non-infected sources. cDNA fragments from infected and non-infected source bile or stool viral isolates can be prepared as above. Radiolabeling the fragments is by random

0055440-021902

1.1 phage was inserted at the unique EcoRI site of the pTZKF1 plasmid. Recombinants carrying the desired insert were identified by hybridization with the isolated 1.33 kilobase fragment, as described in

5 Example 3. One selected plasmid, identified as pTZKF1 (ET1.1), gave the expected 1.33 kb fragment after vector digestion with EcoRI. E. coli strain BB4 infected with the pTZKF1(ET1.1) plasmid has been deposited with the American Type Culture Collection,

10 Rockville, MD, and is identified by ATCC deposit number 67717.

The pTZKF1(ET1.1) plasmid is illustrated at the bottom in Figure 1. The fragment insert has 5' and 3' end regions denoted at A and C, respectively, and an

15 intermediate region, denoted at B. The sequences in these regions were determined by standard dideoxy sequencing and were set forth in an earlier application in this series. The three short sequences (A, B, and C) are from the same insert strand. As will

20 be seen in Example 3, the B-region sequence was actually determined from the opposite strand, so that the B region sequence shown above represents the complement of the sequence in the sequenced strand. The base numbers of the partial sequences are

25 approximate.

Later work in the laboratory of the inventors identified the full sequence, set forth above. Fragments of this total sequence can readily be prepared using restriction endonucleases. Computer

30 analysis of both the forward and reverse sequence has identified a number of cleavage sites.

III. ET-NANB Fragments

According to another aspect, the invention

35 includes ET-NANB-specific fragments or probes which hybridize with ET-NANB genomic sequences or cDNA fragments derived therefrom. The fragments may include full-length cDNA fragments such as described in

Section II, or may be derived from shorter sequence regions within cloned cDNA fragments. Shorter fragments can be prepared by enzymatic digestion of full-length fragments under conditions which yield
5 desired-sized fragments, as will be described in Section IV. Alternatively, the fragments can be produced by oligonucleotide synthetic methods, using sequences derived from the cDNA fragments. Methods or commercial services for producing selected-sequence
10 oligonucleotide fragments are available. Fragments are usually at least 12 nucleotides in length, preferably at least 14, 20, 30 or 50 nucleotides, when used as probes. Probes can be full length or less than 500, preferably less than 300 or 200, nucleotides
15 in length.

To confirm that a given ET-NANB fragment is in fact derived from the ET-NANB viral agent, the fragment can be shown to hybridize selectively with cDNA from infected sources. By way of illustration, to
20 confirm that the 1.33 kb fragment in the pTZKF1(ET1.1) plasmid is ET-NANB in origin, the fragment was excised from the pTZKF1(ET1.1) plasmid, purified, and radiolabeled by random labeling. The radiolabeled fragment was hybridized with fractionated cDNAs from
25 infected and non-infected sources to confirm that the probe reacts only with infected-source cDNAs. This method is illustrated in Example 4, where the above radiolabeled 1.33 kb fragment from pTZKF1(ET1.1) plasmid was examined for binding to cDNAs prepared
30 from infected and non-infected sources. The infected sources are (1) bile from a cynomolgus macaque infected with a strain of virus derived from stool samples from human patients from Burma with known ET-NANB infections and (2) a viral agent derived from the
35 stool sample of a human ET-NANB patient from Mexico. The cDNAs in each fragment mixture were first amplified by a linker/primer amplification method described in Example 4. Fragment separation was on

09651410-021900

agarose gel, followed by Southern blotting and then hybridization to bind the radiolabeled 1.33 kb fragment to the fractionated cDNAs. The lane containing cDNAs from the infected sources showed a smeared band of bound probe, as expected (cDNAs amplified by the linker/primer amplification method would be expected to have a broad range of sizes). No probe binding to the amplified cDNAs from the non-infected sources was observed. The results indicate that the 1.33 kb probe is specific for cDNA fragments associated with ET-NANB infection. This same type of study, using ET 1.1 as the probe, has demonstrated hybridization to ET-NANB samples collected from Tashkent, Somalia, Borneo and Pakistan. Secondly, the fact that the probe is specific for ET-NANB related sequences derived from different continents (Asia, Africa and North America) indicates the cloned ET-NANB Burma sequence (ET1.1) is derived from a common ET-NANB virus or virus class responsible for ET-NANB hepatitis infection worldwide.

In a related confirmatory study, probe binding to fractionated genomic fragments prepared from human or cynomolgus macaque genomic DNA (both infected and uninfected) was examined. No probe binding was observed to either genomic fraction, demonstrating that the ET-NANB fragment is not an endogenous human or cynomolgus genomic fragment and additionally demonstrating that HEV is an RNA virus.

Another confirmation of ET NANB specific sequences in the fragments is the ability to express ET-NANB proteins from coding regions in the fragments and to demonstrated specific sero-reactivity of these proteins with sera collected during documented outbreaks of ET-NANB. Section IV below discusses methods of protein expression using the fragments.

One important use of the ET-NANB-specific fragments is for identifying ET-NANB-derived cDNAs which contain additional sequence information. The

newly identified cDNAs, in turn, yield new fragment probes, allowing further iterations until the entire viral genome is identified and sequenced. Procedures for identifying additional ET-NANB library clones and generating new probes therefrom generally follow the cloning and selection procedures described in Section II.

The fragments (and oligonucleotides prepared based on the sequences given above) are also useful as primers for a polymerase chain reaction method of detecting ET-NANB viral genomic material in a patient sample. This diagnostic method will be described in Section V below.

Two specific genetic sequences derived from the Mexican strain, identified herein as 406.3-2 and 406.4-2, have been identified that encode immunogenic epitopes. This was done by isolating clones which encode epitopes that immunologically react specifically with sera from individuals and experimental animals infected with HEV. Comparison of the isolated sequences with those in the Genbank collection of genetic sequences indicate that these viral sequences are novel. Since these sequences are unique, they can be used to identify the presence of HEV and to distinguish this strain of hepatitis from HAV, HBV, and HCV strains. The sequences are also useful for the design of oligonucleotide probes to diagnose the presence of virus in samples. They can be used for the synthesis of polypeptides that themselves are used in immunoassays. The specific 406.3-2 and 406.4-2 sequences can be incorporated into other genetic material, such as vectors, for ease of expression or replication. They can also be used (as demonstrated above) for identifying similar antigenic regions encoded by related viral strains, such as the Burmese strain.

IV. ET-NANB Proteins

As indicated above, ET-NANB proteins can be prepared by expressing open reading-frame coding regions in ET-NANB fragments. In one preferred approach, the ET-NANB fragments used for protein
 5 expression are derived from cloned cDNAs which have been treated to produce desired-size fragments, and preferably random fragments with sizes predominantly between about 100 to about 300 base pairs. Example 5 describes the preparation of such fragments by DNAs
 10 digestion. Because it is desired to obtain peptide antigens of between about 30 to about 100 amino acids, the digest fragments are preferably size fractionated, for example by gel electrophoresis, to select those in the approximately 100-300 basepair
 15 size range. Alternatively, cDNA libraries constructed directly from HEV-containing sources (e.g., bile or stool) can be screened directly if cloned into an appropriate expression vector (see below).

For example, the ET-NANB proteins expressed
 20 by the 406.3-2 and 406.4-2 sequences (and peptide fragments thereof) are particularly preferred since these proteins have been demonstrated to be immunoreactive with a variety of different human sera, thereby indicating the presence of one or more
 25 epitopes specific for HEV on their surfaces. These clones were identified by direct screening of a gt11 library.

A. Expression Vector

30 The ET-NANB fragments are inserted into a suitable expression vector. One exemplary expression vector is lambda gt11, which contains a unique EcoRI insertion site 53 base pairs upstream of the translation termination codon of the beta-
 35 galactosidase gene. Thus, the inserted sequence will be expressed as a beta-galactosidase fusion protein which contains the N-terminal portion of the beta-galactosidase gene, the heterologous peptide, and

optionally the C-terminal region of the beta-galactosidase peptide (the C-terminal portion being expressed when the heterologous peptide coding sequence does not contain a translation termination codon). This vector also produces a temperature-sensitive repressor (cl857) which causes viral lysogeny at permissive temperatures, e.g., 32°C, and leads to viral lysis at elevated temperatures, e.g., 37°C. Advantages of this vector include: (1) highly efficient recombinant generation, (2) ability to select lysogenized host cells on the basis of host-cell growth at permissive, but not non-permissive, temperatures, and (3) high levels of recombinant fusion protein production. Further, since phage containing a heterologous insert produces an inactive beta-galactosidase enzyme, phage with inserts can be readily identified by a beta-galactosidase colored-substrate reaction.

For insertion into the expression vector, the viral digest fragments may be modified, if needed, to contain selected restriction-site linkers, such as EcoRI linkers, according to conventional procedures. Example 1 illustrates methods for cloning the digest fragments into lambda gt11, which includes the steps of blunt-ending the fragments, ligating with EcoRI linkers, and introducing the fragments into EcoRI-cut lambda gt11. The resulting viral genomic library may be checked to confirm that a relatively large (representative) library has been produced. This can be done, in the case of the lambda gt11 vector, by infecting a suitable bacterial host, plating the bacteria, and examining the plaques for loss of beta-galactosidase activity. Using the procedures described in Example 1, about 50% of the plaques showed loss of enzyme activity.

B. Peptide Antigen Expression

The viral genomic library formed above is screened for production of peptide antigen (expressed as a fusion protein) which is immunoreactive with antiserum from ET-NANB seropositive individuals . In
5 a preferred screening method, host cells infected with phage library vectors are plated, as above, and the plate is blotted with a nitrocellulose filter to transfer recombinant protein antigens produced by the cells onto the filter. The filter is then reacted with
10 the ET-NANB antiserum, washed to remove unbound antibody, and reacted with reporter-labeled, anti-human antibody, which becomes bound to the filter, in sandwich fashion, through the anti-ET-NANB antibody.

Typically phage plaques which are identified
15 by virtue of their production of recombinant antigen of interest are re-examined at a relatively low density for production of antibody-reactive fusion protein. Several recombinant phage clones which produced immunoreactive recombinant antigen were
20 identified in the procedure.

The selected expression vectors may be used for scale-up production, for purposes of recombinant protein purification. Scale-up production is carried out using one of a variety of reported methods for (a)
25 lysogenizing a suitable host, such as E. coli, with a selected lambda gt11 recombinant (b) culturing the transduced cells under conditions that yield high levels of the heterologous peptide, and (c) purifying the recombinant antigen from the lysed cells.

30 In one preferred method involving the above lambda gt11 cloning vector, a high-producer E. coli host, BNN103, is infected with the selected library phage and replica plated on two plates. One of the plates is grown at 32°C, at which viral lysogeny can
35 occur, and the other at 42°C, at which the infecting phage is in a lytic stage and therefore prevents cell growth. Cells which grow at the lower but not the

higher temperature are therefore assumed to be successfully lysogenized.

The lysogenized host cells are then grown under liquid culture conditions which favor high production of the fused protein containing the viral insert, and lysed by rapid freezing to release the desired fusion protein.

C. Peptide Purification

10 The recombinant peptide can be purified by
standard protein purification procedures which may
include differential precipitation, molecular sieve
chromatography, ion-exchange chromatography,
isoelectric focusing, gel electrophoresis and
15 affinity chromatography. In the case of a fused
protein, such as the beta-galactosidase fused protein
prepared as above, the protein isolation techniques
which are used can be adapted from those used in
isolation of the native protein. Thus, for isolation
20 of a soluble betagalactosidase fusion protein, the
protein can be isolated readily by simple affinity
chromatography, by passing the cell lysis material
over a solid support having surface-bound anti-beta-
galactosidase antibody.

D. Viral Proteins

The ET-NANB protein of the invention may also be derived directly from the ET-NANB viral agent. VLPs or protein isolated from stool or liver samples from an infected individual, as above, are one suitable source of viral protein material. The VLPs isolated from the stool sample may be further purified by affinity chromatography prior to protein isolation (see below). The viral agent may also be raised in cell culture, which provides a convenient and potentially concentrated source of viral protein. Co-owned U.S. Patent Application Serial No. 846,757, filed April 1, 1986, describes an immortalized trioma

liver cell which supports NANB infection in cell culture. The trioma cell line is prepared by fusing human liver cells with a mouse/human fusion partner selected for human chromosome stability. Cells
5 containing the desired NANB viral agent can be identified by immunofluorescence methods, employing anti-ET-NANB human antibodies.

The viral agent is disrupted, prior to protein isolation, by conventional methods, which can
10 include sonication, high- or low-salt conditions, or use of detergents.

Purification of ET-NANB viral protein can be carried out by affinity chromatography, using a purified anti-ET-NANB antibody attached according to
15 standard methods to a suitable solid support. The antibody itself may be purified by affinity chromatography, where an immunoreactive recombinant ETNANB protein, such as described above, is attached to a solid support, for isolation of anti-ET-NANB
20 antibodies from an immune serum source. The bound antibody is released from the support by standard methods.

Alternatively, the anti-ET-NANB antibody may be an antiserum or a monoclonal antibody (Mab)
25 prepared by immunizing a mouse or other animal with recombinant ETNANB protein. For Mab production, lymphocytes are isolated from the animal and immortalized with a suitable fusion partner, and successful fusion products which react with the
30 recombinant protein immunogen are selected. These in turn may be used in affinity purification procedures, described above, to obtain native ET-NANB antigen.

V. Utility

35 Although ET-NANB is primarily of interest because of its effects on humans, recent data has shown that this virus is also capable of infecting other animals, especially mammals. Accordingly, any

discussion herein of utility applies to both human and veterinary uses, especially commercial veterinary uses, such as the diagnosis and treatment of pigs, cattle, sheep, horses, and other domesticated animals.

5 A. Diagnostic Methods

 The particles and antigens of the invention, as well as the genetic material, can be used in diagnostic assays. Methods for detecting the presence of ET-NANB hepatitis comprise analyzing a biological
10 sample such as a blood sample, stool sample or liver biopsy specimen for the presence of an analyte associated with ET-NANB hepatitis virus.

 The analyte can be a nucleotide sequence which hybridizes with a probe comprising a sequence of
15 at least about 16 consecutive nucleotides, usually 30 to 200 nucleotides, up to substantially the full sequence of the sequences shown above (cDNA sequences). The analyte can be RNA or cDNA. The analyte is typically a virus particle suspected of
20 being ET-NANB or a particle for which this classification is being ruled out. The virus particle can be further characterized as having an RNA viral genome comprising a sequence at least about 70% homologous to a sequence of at least 12 consecutive
25 nucleotides of the "forward" and "reverse" sequences given above, usually at least about 80% homologous to at least about 60 consecutive nucleotides within the sequences, and may comprise a sequence substantially homologous to the full-length sequences. In order to
30 detect an analyte, where the analyte hybridizes to a probe, the probe may contain a detectable label. Particularly preferred for use as a probe are sequences of consecutive nucleotides derived from the 406.3-2 and 406.4-2 clones described herein, since
35 these clones appear to be particularly diagnostic for HEV.

 The analyte can also comprise an antibody which recognizes an antigen, such as a cell surface

antigen, on a ET-NANB virus particle. The analyte can also be a ET-NANB viral antigen. Where the analyte is an antibody or an antigen, either a labelled antigen or antibody, respectively, can be used to bind to the analyte to form an immunological complex, which can then be detected by means of the label.

Typically, methods for detecting analytes such as surface antigens and/or whole particles are based on immunoassays. Immunoassays can be conducted either to determine the presence of antibodies in the host that have arisen from infection by ET-NANB hepatitis virus or by assays that directly determine the presence of virus particles or antigens. Such techniques are well known and need not be described here in detail. Examples include both heterogeneous and homogeneous immunoassay techniques. Both techniques are based on the formation of an immunological complex between the virus particle or its antigen and a corresponding specific antibody. Heterogeneous assays for viral antigens typically use a specific monoclonal or polyclonal antibody bound to a solid surface. Sandwich assays are becoming increasingly popular. Homogeneous assays, which are carried out in solution without the presence of a solid phase, can also be used, for example by determining the difference in enzyme activity brought on by binding of free antibody to an enzyme-antigen conjugate. A number of suitable assays are disclosed in U.S. Patent Nos. 3,817,837, 4,006,360, 3,996,345.

When assaying for the presence of antibodies induced by ET-NANB viruses, the viruses and antigens of the invention can be used as specific binding agents to detect either IgG or IgM antibodies. Since IgM antibodies are typically the first antibodies that appear during the course of an infection, when IgG synthesis may not yet have been initiated, specifically distinguishing between IgM and IgG antibodies present in the blood stream of a host will

enable a physician or other investigator to determine whether the infection is recent or convalescent. Proteins expressed by the 406.3-2 and 406.4-2 clones described herein and peptide fragments thereof are particularly preferred for use as specific binding agents to detect antibodies since they have been demonstrated to be reactive with a number of different human HEV sera. Further, they are reactive with both acute and convalescent sera.

10 In one diagnostic configuration, test serum is reacted with a solid phase reagent having surface-bound ET-NANB protein antigen. After binding anti-ET-NANB antibody to the reagent and removing unbound serum components by washing, the reagent is reacted with reporter-labeled anti-human antibody to bind reporter to the reagent in proportion to the amount of bound anti-ET-NANB antibody on the solid support. The reagent is again washed to remove unbound labeled antibody, and the amount of reporter associated with the reagent is determined. Typically, the reporter is an enzyme which is detected by incubating the solid phase in the presence of a suitable fluorometric or colorimetric substrate.

25 The solid surface reagent in the above assay prepared by known techniques for attaching protein material to solid support material, such as polymeric beads, dip sticks, or filter material. These attachment methods generally include non-specific adsorption of the protein to the support or covalent attachment of the protein, typically through a free amine group, to a chemically reactive group on the solid support, such as an activate carboxyl, hydroxyl, or aldehyde group.

35 In a second diagnostic configuration, known as a homogeneous assay, antibody binding to a solid support produces some change in the reaction medium which can be directly detected in the medium. Known general types of homogeneous assays proposed

heretofore include (a) spin-labeled reporters, where antibody binding to the antigen is detected by a change in reported mobility (broadening of the spin splitting peaks), (b) fluorescent reporters, where
 5 binding is detected by a change in fluorescence efficiency, (c) enzyme reporters, where antibody binding effects enzyme/substrate interactions, and (d) liposome-bound reporters, where binding leads to liposome lysis and release of encapsulated reporter.
 10 The adaptation of these methods to the protein antigen of the present invention follows conventional methods for preparing homogeneous assay reagents.

In each of the assays described above, the assay method involves reacting the serum from a test
 15 individual with the protein antigen and examining the antigen for the presence of bound antibody. The examining may involve attaching a labeled anti-human antibody to the antibody being examined, either IgM (acute phase) or IgG (convalescent phase), and
 20 measuring the amount of reporter bound to the solid support, as in the first method, or may involve observing the effect of antibody binding on a homogeneous assay reagent, as in the second method.

Also forming part of the invention is an
 25 assay system or kit for carrying out the assay method just described. The kit generally includes a support with surface-bound recombinant protein antigen which is (a) immunoreactive with antibodies present in individuals infected with enterically transmitted
 30 nonA/nonB viral agent and (b) derived from a viral hepatitis agent whose genome contains a region which is homologous to the 1.33 kb DNA EcoRI insert present in plasmid pTZKF1(ET1.1) carried in E. Coli strain BB4, and having ATCC deposit no. 67717. A reporter-
 35 labeled anti-human antibody in the kit is used for detecting surface-bound anti-ET-NANB antibody.

B. Viral Genome Diagnostic Applications

5 The genetic material of the invention can
itself be used in numerous assays as probes for
genetic material present in naturally occurring
infections. One method for amplification of target
nucleic acids, for later analysis by hybridization
assays, is known as the polymerase chain reaction or
PCR technique. The PCR technique can be applied to
detecting virus particles of the invention in
10 suspected pathological samples using oligonucleotide
primers spaced apart from each other and based on the
genetic sequence set forth above. The primers are
complementary to opposite strands of a double stranded
DNA molecule and are typically separated by from about
15 50 to 450 nt or more (usually not more than 2000 nt).
This method entails preparing the specific
oligonucleotide primers and then repeated cycles of
target DNA denaturation, primer binding, and
extension with a DNA polymerase to obtain DNA
20 fragments of the expected length based on the primer
spacing. Extension products generated from one primer
serve as additional target sequences for the other
primer. The degree of amplification of a target
sequence is controlled by the number of cycles that
25 are performed and is theoretically calculated by the
simple formula 2^n where n is the number of cycles.
Given that the average efficiency per cycle ranges
from about 65% to 85%, 25 cycles produce from 0.3 to
4.8 million copies of the target sequence. The PCR
30 method is described in a number of publications,
including Saiki et al., Science (1985) 230:1350-1354;
Saiki et al., Nature (1986) 324:163-166; and Scharf et
al., Science (1986) 233:1076-1078. Also see U.S.
Patent Nos. 4,683,194; 4,683,195; and 4,683,202.

35 The invention includes a specific diagnostic
method for determination of ET-NANB viral agent, based
on selective amplification of ET-NANB fragments. This
method employs a pair of single-strand primers derived

from non-homologous regions of opposite strands of a DNA duplex fragment, which in turn is derived from an enterically transmitted viral hepatitis agent whose genome contains a region which is homologous to the

5 1.33 kb DNA EcoRI insert present in plasmid pTZKF1(ET1.1) carried in E. coli strain BB4, and having ATCC deposit no. 67717. These "primer fragments," which form one aspect of the invention, are prepared from ET-NANB fragments such as described

10 in Section III above. The method follows the process for amplifying selected nucleic acid sequences as disclosed in U.S. Patent No. 4,683,202, as discussed above.

15 C. Peptide Vaccine

Any of the antigens of the invention can be used in preparation of a vaccine. A preferred starting material for preparation of a vaccine is the particle antigen isolated from bile. The antigens are

20 preferably initially recovered as intact particles as described above. However, it is also possible to prepare a suitable vaccine from particles isolated from other sources or non-particle recombinant antigens. When non-particle antigens are used (typically soluble

25 antigens), proteins derived from the viral envelope or viral capsid are preferred for use in preparing vaccines. These proteins can be purified by affinity chromatography, also described above.

If the purified protein is not immunogenic

30 per se, it can be bound to a carrier to make the protein immunogenic. Carriers include bovine serum albumin, keyhole limpet hemocyanin and the like. It is desirable, but not necessary, to purify antigens to be substantially free of human protein. However, it is

35 more important that the antigens be free of proteins, viruses, and other substances not of human origin that may have been introduced by way of, or contamination of, the nutrient medium, cell lines,

tissues, or pathological fluids from which the virus is cultured or obtained.

Vaccination can be conducted in conventional fashion. For example, the antigen, whether a viral particle or a protein, can be used in a suitable diluent such as water, saline, buffered salines, complete or incomplete adjuvants, and the like. The immunogen is administered using standard techniques for antibody induction, such as by subcutaneous administration of physiologically compatible, sterile solutions containing inactivated or attenuated virus particles or antigens. An immune response producing amount of virus particles is typically administered per vaccinating injection, typically in a volume of one milliliter or less.

A specific example of a vaccine composition includes, in a pharmacologically acceptable adjuvant, a recombinant protein or protein mixture derived from an enterically transmitted nonA/nonB viral hepatitis agent whose genome contains a region which is homologous to the 1.33 kb DNA EcoRI insert present in plasmid pTZKF1(ET1.1) carried in E. coli strain BB4, and having ATCC deposit no. 67717. The vaccine is administered at periodic intervals until a significant titer of anti-ET-NANB antibody is detected in the serum. The vaccine is intended to protect against ET-NANB infection.

Particularly preferred are vaccines prepared using proteins expressed by the 406.3-2 and 406.4-2 clones described herein and equivalents thereof, including fragments of the expressed proteins. Since these clones have already been demonstrated to be reactive with a variety of human HEV-positive sera, their utility in protecting against a variety of HEV strains is indicated.

D. Prophylactic and Therapeutic
Antibodies and Antisera

00551410-021902

In addition to use as a vaccine, the compositions can be used to prepare antibodies to ET-NANB virus particles. The antibodies can be used directly as antiviral agents. To prepare antibodies, a host animal is immunized using the virus particles or, as appropriate, non-particle antigens native to the virus particle are bound to a carrier as described above for vaccines. The host serum or plasma is collected following an appropriate time interval to provide a composition comprising antibodies reactive with the virus particle. The gamma globulin fraction or the IgG antibodies can be obtained, for example, by use of saturated ammonium sulfate or DEAE Sephadex, or other techniques known to those skilled in the art. The antibodies are substantially free of many of the adverse side effects which may be associated with other anti-viral agents such as drugs.

The antibody compositions can be made even more compatible with the host system by minimizing potential adverse immune system responses. This is accomplished by removing all or a portion of the FC portion of a foreign species antibody or using an antibody of the same species as the host animal, for example, the use of antibodies from human/human hybridomas.

The antibodies can also be used as a means of enhancing the immune response since antibody-virus complexes are recognized by macrophages. The antibodies can be administered in amounts similar to those used for other therapeutic administrations of antibody. For example, pooled gamma globulin is administered at 0.02-0.1 ml/lb body weight during the early incubation of other viral diseases such as rabies, measles and hepatitis B to interfere with viral entry into cells. Thus, antibodies reactive with the ET-NANB virus particle can be passively administered alone or in conjunction with another anti-viral agent to a host infected with an ET-NANB virus to enhance the immune

response and/or the effectiveness of an antiviral drug.

Alternatively, anti-ET-NANB-virus antibodies can be induced by administering anti-idiotypic antibodies as immunogens. Conveniently, a purified anti-ET-NANB-virus antibody preparation prepared as described above is used to induce anti-idiotypic antibody in a host animal. The composition is administered to the host animal in a suitable diluent. Following administration, usually repeated administration, the host produces anti-idiotypic antibody. To eliminate an immunogenic response to the Fc region, antibodies produced by the same species as the host animal can be used or the Fc region of the administered antibodies can be removed. Following induction of anti-idiotypic antibody in the host animal, serum or plasma is removed to provide an antibody composition. The composition can be purified as described above for anti-ET-NANB virus antibodies, or by affinity chromatography using anti-ET-NANB-virus antibodies bound to the affinity matrix. The anti-idiotypic antibodies produced are similar in conformation to the authentic ET-NANB antigen and may be used to prepare an ET-NANB vaccine rather than using a ET-NANB particle antigen.

When used as a means of inducing anti-ET-NANB virus antibodies in a patient, the manner of injecting the antibody is the same as for vaccination purposes, namely intramuscularly, intraperitoneally, subcutaneously or the like in an effective concentration in a physiologically suitable diluent with or without adjuvant. One or more booster injections may be desirable. The anti-idiotypic method of induction of anti-ET-NANB virus antibodies can alleviate problems which may be caused by passive administration of anti-ET-NANB-virus antibodies, such as an adverse immune response, and those associated

subject to splenectomy. Epstein-Barr virus (EBV) can be used to immortalize human lymphocytes or a human fusion partner can be used to produce human-human hybridomas. Primary in vitro immunization with
5 peptides can also be used in the generation of human monoclonal antibodies.

Antibodies secreted by the immortalized cells are screened to determine the clones that secrete antibodies of the desired specificity. For
10 monoclonal anti-virus particle antibodies, the antibodies must bind to ET-NANB virus particles. For monoclonal anti-idiotypic antibodies, the antibodies must bind to anti-virus particle antibodies. Cells producing antibodies of the desired specificity are
15 selected.

The following examples illustrate various aspects of the invention, but are in no way intended to limit the scope thereof.

20 Material

The materials used in the following Examples were as follows:

Enzymes: DNase I and alkaline phosphatase were obtained from Boehringer Mannheim Biochemicals
25 (BMB, Indianapolis, IN); EcoRI, EcoRI methylase, DNA ligase, and DNA Polymerase I, from New England Biolabs (NEB, Beverly MA); and RNase A was obtained from Sigma (St. Louis, MO) .

Other reagents: EcoRI linkers were obtained
30 from NEB; and nitro blue tetrazolium (NBT), S-bromo-4-chloro-3-indolyl phosphate (BCIP) S-bromo-4-chloro-3-indolyl-B-D-galactopyranoside (Xgal) and isopropyl B-D-thiogalactopyranoside (IPTG) were obtained from Sigma.

35 cDNA synthesis kit and random priming labeling kits are available from Boehringer-Mannheim Biochemical (BMB, Indianapolis, IN).

Example 1

Preparing cDNA Library

A. Source of ET-NANB virus

Two cynomolgus monkeys (cynos) were
5 intravenously injected with a 10% suspension of a
stool pool obtained from a second-passage cyno (cyno
#37) infected with a strain of ET-NANB virus isolated
from Burma cases whose stools were positive for ET-
NANB, as evidenced by binding of 27-34 nm virus-like
10 particles (VLPs) in the stool to immune serum from a
known ETNANB patient. The animals developed elevated
levels of alanine aminotransferase (ALT) between 24-36
days after inoculation, and one excreted 27-34 nm
VLPs in its bile in the pre-acute phase of infection.

15 The bile duct of each infected animal was
cannulated and about 1-3 cc of bile was collected
daily. RNA was extracted from one bile specimen (cyno
#121) by hot phenol extraction, using a standard RNA
isolation procedure. Double-strand cDNA was formed
20 from the isolated RNA by a random primer for first-
strand generation, using a cDNA synthesis kit obtained
from Boehringer-Mannheim (Indianapolis, IN).

B. Cloning the Duplex Fragments

25 The duplex cDNA fragments were blunt-ended
with T4 DNA polymerase under standard conditions
(Maniatis, p. 118), then extracted with
phenol/chloroform and precipitated with ethanol. The
blunt-ended material was ligated with EcoRI linkers
30 under standard conditions (Maniatis, pp. 396-397) and
digested with EcoRI to remove redundant linker ends.
Non-ligated linkers were removed by sequential
isopropanol precipitation.

Lambda gt10 phage vector (Huynh) was
35 obtained from Promega Biotec (Madison, WI). This
cloning vector has a unique EcoRI cloning site in the
phage CI repressor gene. The cDNA fragments from above
were introduced into the EcoRI site by mixing 0.5 -

1.0 μ g EcoRI-cleaved gt10, 0.5-3 μ l of the above
duplex fragments, 0.5 μ l 10X ligation buffer, 0.5 μ l
ligase (200 units), and distilled water to 5 μ l. The
mixture was incubated overnight at 14°C, followed by
5 in vitro packaging, according to standard methods
(Maniatis, pp. 256-268).

The packaged phage were used to infect an E. coli hfl strain, such as strain HG415. Alternatively,
E. coli, strain C600 hfl available from Promega
10 Biotec, Madison, WI, could be used. The percentage of
recombinant plaques obtained with insertion of the
EcoRI-ended fragments was less than 5% by analysis of
20 random plaques.

The resultant cDNA library was plated and
15 phage were eluted from the selection plates by
addition of elution buffer. After DNA extraction from
the phage, the DNA was digested with EcoRI to release
the heterogeneous insert population, and the DNA
fragments were fractionated on agarose to remove phage
20 fragments. The 500-4,000 basepair inserts were
isolated and recloned into lambda gt10 as above, and
the packaged phage was used to infect E. coli strain
HG415. The percentage of successful recombinants was
greater than 95%. The phage library was plated on E.
25 coli strain HG415, at about 5,000 plaques/plate, on a
total of 8 plates.

Example 2

Selecting ET-NANB Cloned Fragments

30 A. cDNA Probes

Duplex cDNA fragments from noninfected and
ETNANB-infected cynomolgus monkeys were prepared as in
Example 1. The cDNA fragments were radiolabeled by
random priming, using a random-priming labeling kit
35 obtained from Boehringer-Mannheim (Indianapolis, IN).

B. Clone Selection

The plated cDNA library from Example 1 was transferred to each of two nitrocellulose filters, and the phage DNA was fixed on the filters by baking, according to standard methods (Maniatis, pp. 320323).
 5 The duplicate filters were hybridized with either infected-source or control CDNA probes from above. Autoradiographs of the filters were examined to identify library clones which hybridized with radiolabeled CDNA probes from infected source only,
 10 i.e., did not hybridize with cDNA probes from the non-infected source. Sixteen such clones, out of a total of about 40,000 clones examined, were identified by this subtraction selection method.

Each of the sixteen clones was picked and
 15 replated at low concentration on an agar plate. The clones on each plate were transferred to two nitrocellulose ag duplicate lifts, and examined for hybridization to radiolabeled cDNA probes from infected and noninfected sources, as above. Clones were selected
 20 which showed selective binding for infected-source probes (i.e., binding with infected-source probes and substantially no binding with non-infected-source probes). One of the clones which bound selectively to probe from infected source was isolated for further
 25 study. The selected vector was identified as lambda gt10-1.1, indicated in Figure 1.

Example 3

ET-NANB Sequence

30 Clone lambda gt10-1.1 from Example 2 was digested with EcoRI to release the heterologous insert, which was separated from the vector fragments by gel electrophoresis. The electrophoretic mobility of the fragment was consistent with a 1.33 kb fragment. This
 35 fragment, which contained EcoRI ends, was inserted into the EcoRI site of a pTZKF1 vector, whose construction and properties are described in co-owned U.S. patent application for "Cloning Vector System and

Method for Rare Clone Identification", Serial No. 125, 650, filed November 25, 1987. Briefly, and as illustrated in Figure 1, this plasmid contains a unique EcoRI site adjacent a T7 polymerase promoter site, and plasmid and phage origins of replication. The sequence immediately adjacent each side of the EcoRI site is known. E. coli BB4 bacteria, obtained from Stratagene (La Jolla, CA, were transformed with the plasmid.

Radiolabeled ET-NANB probe was prepared by excising the 1.33 kb insert from the lambda gt10-1.1 phage in Example 2, separating the fragment by gel electrophoresis, and randomly labeling as above. Bacteria transfected with the above pTZKF1 and containing the desired ET-NANB insert were selected by replica lift and hybridization with the radiolabeled ET-NANB probe, according to methods outlined in Example 2.

One bacterial colony containing a successful recombinant was used for sequencing a portion of the 1.33 kb insert. This isolate, designated pTZKF1(ET1.1), has been deposited with the American Type Culture Collection, and is identified by ATCC deposit no. 67717. Using a standard dideoxy sequencing procedure, and primers for the sequences flanking the EcoRI site, about 200-250 basepairs of sequence from the 5'-end region and 3'-end region of the insert were obtained. The sequences are given above in Section II. Later sequencing by the same techniques gave the full sequence in both directions, also given above.

Example 4

Detecting ET-NANB Sequences

cDNA fragment mixtures from the bile of noninfected and ET-NANB-infected cynomolgus monkeys were prepared as above. The cDNA fragments obtained from human stool samples were prepared as follows.

Thirty ml of a 10% stool suspension obtained from an individual from Mexico diagnosed as infected with ET-NANB as a result of an ET-NANB outbreak, and a similar volume of stool from a healthy, non-infected individual, were layered over a 30% sucrose density gradient cushion, and centrifuged at 25,000 x g for 6 hr in an SW27 rotor, at 15°C. The pelleted material from the infected-source stool contained 27-34 nm VLP particles characteristic of ET-NANB infection in the infected-stool sample. RNA was isolated from the sucrose-gradient pellets in both the infected and non-infected samples, and the isolated RNA was used to produce cDNA fragments as described in Example 1.

The cDNA fragment mixtures from infected and non-infected bile source, and from infected and non-infected human-stool source were each amplified by a novel linker/primer replication method described in co-owned patent application serial number 07/208,512 for "DNA Amplification and Subtraction Technique," filed June 17, 1988. Briefly, the fragments in each sample were blunt-ended with DNA Pol I then extracted with phenol/chloroform and precipitated with ethanol. The blunt-ended material was ligated with linkers having the following sequence (top or 5' sequence has SEQ ID NO.21; bottom or 3' sequence has SEQ ID NO.22):

5'-GGAATTCGCGGCCGCTCG-3'
3'-TTCCTTAAGCGCCGGCGAGC-5'

The duplex fragments were digested with NruI to remove linker dimers, mixed with a primer having the sequence 5'-GGAATTCGCGGCCGCTCG-3', and then heat denatured and cooled to room temperature to form single-strand DNA/primer complexes. The complexes were replicated to form duplex fragments by addition of *Thermus aquaticus* (Taq) polymerase and all four deoxynucleotides. The replication procedures, involving successive strand denaturation, formation of

strand/primer complexes, and replication, was repeated 25 times.

The amplified cDNA sequences were fractionated by agarose gel electrophoresis, using a 2% agarose matrix. After transfer of the DNA fragments from the agarose gels to nitrocellulose paper, the filters were hybridized to a random-labeled 32p probe prepared by (i) treating the pTZKF1(ET1.1) plasmid from above with EcoRI, (ii) isolating the released 1.33 kb ET-NANB fragment, and (iii) randomly labeling the isolated fragment. The probe hybridization was performed by conventional Southern blotting methods (Maniatis, pp. 382-389). Figure 2 shows the hybridization pattern obtained with cDNAs from infected (I) and non-infected (N) bile sources (2A) and from infected (I) and noninfected (N) human stool sources (2B). As seen, the ET-NANB probe hybridized with fragments obtained from both of the infected sources, but was non-homologous to sequences obtained from either of the non-infected sources, thus confirming the specificity of derived sequence.

Southern blots of the radiolabeled 1.33 kb fragment with genomic DNA fragments from both human and cynomolgus-monkey DNA were also prepared. No probe hybridization to either of the genomic fragment mixtures was observed, confirming that the ET-NANB sequence is exogenous to either human or cynomolgus genome.

30

Example 5

Expressing ET-NANB Proteins

A. Preparing ET-NANB Coding Sequences

The pTZKF1(ET1.1) plasmid from Example 2 was digested with EcoRI to release the 1.33 kb ET-NANB insert which was purified from the linearized plasmid by gel electrophoresis. The purified fragment was suspended in a standard digest buffer (0.5M Tris HCl, pH 7.5; 1 mg/ml BSA; 10mM MnCl₂) to a concentration of

09551410 "021502

about 1 mg/ml and digested with DNase I at room temperature for about 5 minutes. These reaction conditions were determined from a prior calibration study, in which the incubation time required to
5 produce predominantly 100-300 basepair fragments was determined. The material was extracted with phenol/chloroform before ethanol precipitation.

The fragments in the digest mixture were blunt-ended and ligated with EcoRI linkers as in
10 Example 1. The resultant fragments were analyzed by electrophoresis (5-10V/cm) on 1.2% agarose gel, using PhiX174/HaeIII and lambda/HindIII size markers. The 100-300 bp fraction was eluted onto NA45 strips (Schleicher and Schuell), which were then placed into
15 1.5 ml microtubes with eluting solution (1 M NaCl, 50 mM arginine, pH 9.0), and incubated at 67°C for 30-60 minutes. The eluted DNA was phenol/chloroform extracted and then precipitated with two volumes of ethanol. The pellet was resuspended in 20 μ l TE (0.01
20 M Tris HCl, pH 7.5, 0.001 M EDTA).

B. Cloning in an Expression Vector

Lambda gt11 phage vector (Huynh) was obtained from Promega Biotec (Madison, WI). This
25 cloning vector has a unique EcoRI cloning site 53 base pairs upstream from the beta-galactosidase translation termination codon. The genomic fragments from above, provided either directly from coding sequences (Example 5) or after amplification of cDNA (Example
30 4), were introduced into the EcoRI site by mixing 0.5-1.0 μ g EcoRI-cleaved gt11, 0.3-3 μ l of the above sized fragments, 0.5 μ l 10X ligation buffer (above), 0.5 μ l ligase (200 units), and distilled water to 5 μ l. The mixture was incubated overnight at 14°C, followed by
35 in vitro packaging, according to standard methods (Maniatis, pp. 256-268).

The packaged phage were used to infect E. coli strain KM392, obtained from Dr. Kevin Moore, DNAX

(Palo Alto, CA). Alternatively, E. Coli strain Y1090, available from the American Type Culture Collection (ATCC #37197), could be used. The infected bacteria were plated and the resultant colonies were checked for loss of beta-galactosidase activity-(clear plaques) in the presence of X-gal using a standard X-gal substrate plaque assay method (Maniatis). About 50% of the phage plaques showed loss of beta-galactosidase enzyme activity (recombinants).

10

C. Screening for ET-NANB Recombinant Proteins

ET-NANB convalescent antiserum was obtained from patients infected during documented ET-NANB outbreaks in Mexico, Borneo, Pakistan, Somalia, and Burma. The sera were immunoreactive with VLPs in stool specimens from each of several other patients with ET-NANB hepatitis.

A lawn of E. coli KM392 cells infected with about 104 pfu of the phage stock from above was prepared on a 150 mm plate and incubated, inverted, for 5-8 hours at 37°C. The lawn was overlaid with a nitrocellulose sheet, causing transfer of expressed ETNANB recombinant protein from the plaques to the paper. The plate and filter were indexed for matching corresponding plate and filter positions.

The filter was washed twice in TBST buffer (10 mM Tris, pH 8.0, 150 mM NaCl, 0.05% Tween 20), blocked with AIB (TBST buffer with 1% gelatin), washed again in TBST, and incubated overnight after addition of antiserum (diluted to 1:50 in AIB, 12-15 ml/plate). The sheet was washed twice in TBST and then contacted with enzyme-labeled anti-human antibody to attach the labeled antibody at filter sites containing antigen recognized by the antiserum. After a final washing, the filter was developed in a substrate medium containing 33 μ l NBT (50 mg/ml stock solution maintained at 4°C) mixed with 16 μ l BCIP (50 mg/ml stock solution maintained at 4°C) in 5 ml of alkaline

phosphatase buffer (100 mM Tris, 9.5, 100 mM NaCl, 5 mM MgCl₂). Purple color appeared at points of antigen production, as recognized by the antiserum.

5 D. Screening Plating

The areas of antigen production determined in the previous step were replated at about 100-200 pfu on an 82 mm plate. The above steps, beginning with a 5-8 hour incubation, through NBT-BCIP development, were repeated in order to plaque purify phage secreting an antigen capable of reacting with the ET-NANB antibody. The identified plaques were picked and eluted in phage buffer (Maniatis, p. 443).

15 E. Epitope Identification

A series of subclones derived from the original pTZKF1 (ET1.1) plasmid from Example 2 were isolated using the same techniques described above. Each of these five subclones were immunoreactive with a pool of anti-ET antisera noted in C. The subclones contained short sequences from the "reverse" sequence set forth previously. The beginning and ending points of the sequences in the subclones (relative to the full "reverse" sequence), are identified in the table below.

TABLE 1

	<u>Subclone</u>	<u>Position in "Reverse" Sequence</u>	
		<u>5'-end</u>	<u>3'-end</u>
5	Y1	522	643
	Y2	594	667
	Y3	508	665
	Y4	558	752
10	Y5	545	665

Since all of the gene sequences identified in the table must contain the coding sequence for the epitope, it is apparent that the coding sequence for the epitope falls in the region between nucleotide 594 (5'-end) and 643 (3'-end). Genetic sequences equivalent to and complementary to this relatively short sequence are therefore particularly preferred aspects of the present invention, as are peptides produced using this coding region.

A second series of clones identifying an altogether different epitope was isolated with only Mexican serum.

TABLE 2

	<u>Subclone</u>	<u>Position in "Forward" Sequence</u>	
		<u>5' end</u>	<u>3' end</u>
	ET 2-2	2	193
30	ET 8-3	2	135
	ET 9-1	2	109
	ET 13-1	2	101

The coding system for this epitope falls between nucleotide 2 (5'-end) and 101 (3'-end). Genetic sequences related to this short sequence are therefore also preferred, as are peptides produced using this coding region.

Two particularly preferred subclones for use in preparing polypeptides containing epitopes specific for HEV are the 406.3-2 and 406.4-2 clones whose sequences are set forth above. These sequences were isolated from an amplified cDNA library derived from a Mexican stool. Using the techniques described in this section, polypeptides expressed by these clones have been tested for immunoreactivity against a number of different human HEV-positive sera obtained from sources around the world. As shown in Table 3 below, 8 sera immunoreactive with the polypeptide expressed by the 406.4-2, and 6 sera immunoreacted with polypeptide expressed by the 406.3-2 clone.

For comparison, the Table also shows reactivity of the various human sera with the Y2 clone identified in Table 1 above. Only one of the sera reacted with the polypeptide expressed by this clone. No immunoreactivity was seen for normal expression products of the gtl1 vector.

Table 3
Immunoreactivity of HEV Recombinant
Proteins: Human Sera

Sera	Source	Stage ¹	406.3-2	406.4-2	Y2	λgt11
FVH-21	Burma	A	-	-	-	-
FVH-8	Burma	A	-	+	+	-
SOM-19	Somalia	A	+	+	-	-
SOM-20	Somalia	A	+	+	-	-
IM-35	Borneo	A	+	+	-	-
IM-36	Borneo	A	-	-	-	-
PAK-1	Pakistan	A	+	+	-	-
FFI-4	Mexico	A	+	+	-	-

FFI-125	Mexico	A	-	+	-	-
F 387 IC	Mexico	C	+	+	ND	-
Normal	U.S.A.	-	-	-	-	-

5 1A = acute; C = convalescent

While the invention has been described with reference to particular embodiments, methods, construction and use, it will be apparent to those skilled in the art that various changes and modifications can be made without departing from the invention.

10

0531410-061902